OPKO Health (OPK) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Opko Health, Inc.	'
Entity Central Index Key	'0000944809	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	407,989,487

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'		'
Cash and cash equivalents	$155,834	[1]	$27,361	[1]
Marketable securities	25,004	[1]	0	[1]
Accounts receivable, net	21,372	[1]	21,162	[1]
Inventory, net	19,516	[1]	22,261	[1]
Prepaid expenses and other current assets	19,551	[1]	7,873	[1]
Total current assets	241,277	[1]	78,657	[1]
Property, plant, equipment, and investment properties, net	17,027	[1]	16,526	[1]
Intangible assets, net	77,333	[1]	84,238	[1]
In-process research and development	793,312	[1]	11,546	[1]
Goodwill	222,340	[1]	80,450	[1]
Investments, net	24,690	[1]	15,636	[1]
Other assets	7,003	[1]	2,777	[1]
Total assets	1,382,982	[1]	289,830	[1]
Current liabilities:	'		'
Accounts payable	13,631	[1]	10,200	[1]
Accrued expenses	43,269	[1]	24,656	[1]
Current portion of lines of credit and notes payable	14,477	[1]	17,526	[1]
Total current liabilities	71,377	[1]	52,382	[1]
3.00% convertible senior notes, net of discount and estimated fair value of embedded derivatives	208,917	[1]	0	[1]
Other long-term liabilities, principally contingent consideration and deferred tax liabilities	234,762	[1]	34,168	[1]
Total long-term liabilities	443,679	[1]	34,168	[1]
Total liabilities	515,056	[1]	86,550	[1]
Commitments and contingencies:	'	[1]	'	[1]
Series D Preferred Stock - $0.01 par value, 2,000,000 shares authorized; no shares issued or outstanding at September 30, 2013 and 1,129,032 shares issued and outstanding (liquidation value of $30,595) at December 31, 2012	0	[1]	24,386	[1]
Equity:	'		'
Common Stock - $0.01 par value, 500,000,000 shares authorized; 408,903,912 and 305,560,763 shares issued at September 30, 2013 and December 31, 2012, respectively	4,089	[1]	3,056	[1]
Treasury Stock - 2,293,056 shares at both September 30, 2013 and December 31, 2012	-7,457	[1]	-7,457	[1]
Additional paid-in capital	1,357,235	[1]	565,201	[1]
Accumulated other comprehensive income	3,237	[1]	7,356	[1]
Accumulated deficit	-486,377	[1]	-388,770	[1]
Total shareholders’ equity	870,727	[1]	179,386	[1]
Noncontrolling interests	-2,801	[1]	-492	[1]
Total equity	867,926	[1]	178,894	[1]
Total liabilities, Series D Preferred Stock, and equity	1,382,982	[1]	289,830	[1]
Series A Preferred Stock	'		'
Equity:	'		'
Preferred Stock	0	[1]	0	[1]
Series C Preferred Stock	'		'
Equity:	'		'
Preferred Stock	$0	[1]	$0	[1]
[1]	As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Convertible senior notes interest rate	3.00%	'
Series D Preferred stock, par value (in dollars per share)	$0.01	$0.01
Series D Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Series D Preferred stock, shares issued (in shares)	0	1,129,032
Series D Preferred stock, shares outstanding (in shares)	0	1,129,032
Liquidation preference, preferred stock value	$0	$30,595,000
Common Stock, par value (in dollars per share)	$0.01	$0.01
Common Stock, shares authorized (in shares)	500,000,000	500,000,000
Common Stock, shares issued (in shares)	408,903,912	305,560,763
Treasury stock, shares (in shares)	2,293,056	2,293,056
Total assets in variable interest entity	5,900,000	5,600,000
Total liability in variable interest entity	$8,700,000	$5,500,000
Series A Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.01	$0.01
Preferred Stock, shares authorized (in shares)	4,000,000	4,000,000
Preferred Stock, shares issued (in shares)	0	0
Preferred Stock, shares outstanding (in shares)	0	0
Series C Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.01	$0.01
Preferred Stock, shares authorized (in shares)	500,000	500,000
Preferred Stock, shares issued (in shares)	0	0
Preferred Stock, shares outstanding (in shares)	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
Products	$16,563	$11,495	$50,708	$30,051
Revenue from services	2,770	100	9,050	332
Revenue from transfer of intellectual property	1,308	200	16,080	400
Total revenues	20,641	11,795	75,838	30,783
Costs and expenses:	'	'	'	'
Costs of revenues	11,952	7,487	36,812	19,028
Selling, general and administrative	13,572	7,322	39,875	17,428
Research and development	11,085	3,621	30,552	12,942
Change in fair value of contingent consideration	252	556	4,173	2,665
Amortization of intangible assets	2,790	2,178	8,192	6,277
Total costs and expenses	39,651	21,164	119,604	58,340
Operating loss from continuing operations	-19,010	-9,369	-43,766	-27,557
Other income and (expense), net:	'	'	'	'
Interest income	88	49	237	123
Interest expense	-3,409	-393	-10,148	-975
Fair value changes of derivative instruments, net	-27,793	169	-38,691	1,309
Other income (expense), net	-7,787	55	2,571	-30
Other income and (expense), net	-38,901	-120	-46,031	427
Loss from continuing operations before income taxes and investment losses	-57,911	-9,489	-89,797	-27,130
Income tax provision (benefit)	1,290	-128	2,258	89
Loss from continuing operations before investment losses	-59,201	-9,361	-92,055	-27,219
Loss from investments in investees	-1,600	-468	-7,861	-1,464
Income (Loss) from Continuing Operations Attributable to Parent	-60,801	-9,829	-99,916	-28,683
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	0	183	0	183
Net loss	-60,801	-9,646	-99,916	-28,500
Less: Net loss attributable to noncontrolling interests	-803	0	-2,309	0
Net loss attributable to common shareholders before preferred stock dividend	-59,998	-9,646	-97,607	-28,500
Preferred stock dividend	0	-560	-420	-1,680
Net loss attributable to common shareholders	($59,998)	($10,206)	($98,027)	($30,180)
Income (Loss) from Continuing Operations, Per Basic and Diluted Share	($0.17)	($0.03)	($0.29)	($0.10)
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic and Diluted Share	$0	$0	$0	$0
Basic and diluted loss per share (in dollars per share)	($0.17)	($0.03)	($0.29)	($0.10)
Weighted Average Number of Shares Outstanding, Basic and Diluted	360,638,527	298,103,882	336,942,515	297,762,469

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net loss attributable to common shareholders	($59,998)	($10,206)	($98,027)	($30,180)
Other comprehensive income (loss), net of tax:	'	'	'	'
Change in foreign currency translation	367	1,960	-1,395	2,570
Available for sale investments:	'	'	'	'
Change in other unrealized gains, net	40	322	1,869	5,527
Less: reclassification adjustments for gains included in net loss, net of tax	0	0	-4,593	0
Comprehensive loss	($59,591)	($7,924)	($102,146)	($22,083)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Equity (Unaudited) (USD $)

Total

Silcon [Member]

Cytochroma [Member]

PROLOR [Member]

Farmadiet [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Treasury

Additional Paid-In Capital

Additional Paid-In Capital

Additional Paid-In Capital

Additional Paid-In Capital

Additional Paid-In Capital

Acumulated Other Comprehensive Income (Loss)

Accumulated Deficit

Noncontrolling Interests

Series D Preferred Stock

Series D Preferred Stock

Series D Preferred Stock

Notes [Member]

Notes [Member]

Notes [Member]

In Thousands, except Share data, unless otherwise specified

Silcon [Member]

Cytochroma [Member]

PROLOR [Member]

Farmadiet [Member]

Silcon [Member]

Cytochroma [Member]

PROLOR [Member]

Farmadiet [Member]

Common Stock [Member]

Additional Paid-In Capital

Common Stock [Member]

Additional Paid-In Capital

Beginning balance (audited) at Dec. 31, 2012

$178,894

[1]

'

'

'

'

$3,056

'

'

'

'

($7,457)

$565,201

'

'

'

'

$7,356

($388,770)

($492)

'

'

'

'

'

'

Beginning balance (audited), shares at Dec. 31, 2012

'

'

'

'

'

305,560,763

'

'

'

'

2,293,056

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity-based compensation expense

7,411

'

'

'

'

'

'

'

'

'

'

7,411

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of Common Stock options

4,435

'

'

'

'

36

'

'

'

'

'

4,399

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of Common Stock options, shares

'

'

'

'

'

3,604,783

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of Common Stock warrants

626

'

'

'

'

12

'

'

'

'

'

614

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of Common Stock warrants, shares

'

'

'

'

'

1,213,679

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series D Preferred Stock dividend

'

'

'

'

'

'

'

'

'

'

'

-3,015

'

'

'

'

'

'

'

-3,015

'

'

'

'

'

Conversion of Series D Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24,386

113

24,273

20,839

24

20,815

Conversion of Series D Preferred Stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,290,320

'

'

2,396,145

'

Issuance of Common Stock in connection with acquisition

'

436

146,902

586,643

'

'

1

205

637

'

'

'

435

146,697

586,006

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Share, Deferred Payment

'

'

'

'

'

'

'

'

'

585,703

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Deferred Payment

'

'

'

'

4,404

'

'

'

'

5

'

'

'

'

'

4,399

'

'

'

'

'

'

'

'

'

Issuance of Common Stock in connection with acquisition, shares

'

'

'

'

'

'

64,684

20,517,030

63,670,805

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss attributable to common shareholders before preferred stock dividend

-97,607

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-97,607

'

'

'

'

'

'

'

Net loss attributable to noncontrolling interests

-2,309

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,309

'

'

'

'

'

'

Other comprehensive loss

-4,119

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,119

'

'

'

'

'

'

'

'

Ending balance (unaudited) at Sep. 30, 2013

$867,926

[1]

'

'

'

'

$4,089

'

'

'

'

($7,457)

$1,357,235

'

'

'

'

$3,237

($486,377)

($2,801)

'

'

'

'

'

'

Ending balance (audited), shares at Sep. 30, 2013

'

'

'

'

'

408,903,912

'

'

'

'

2,293,056

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Condensed_Consolidated_Stateme3

Condensed Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2013
Convertible senior notes interest rate	3.00%
Silcon [Member]	'
Closing share price at September 30, 2013 for investments available for sale	$6.73
Cytochroma [Member]	'
Closing share price at September 30, 2013 for investments available for sale	$7.16
PROLOR [Member]	'
Closing share price at September 30, 2013 for investments available for sale	$8.49
Farmadiet [Member]	'
Closing share price at September 30, 2013 for investments available for sale	$7.52

Condensed_Consolidated_Stateme4

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012
Cash flows from operating activities:	'		'
Net loss	($99,916)		($28,500)
Income from discontinued operations, net of tax	0		-183
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Depreciation and amortization	10,648		7,447
Non-cash interest on convertible senior notes	4,250		0
Amortization of deferred financing costs	993		0
Losses from investments in investees	7,861		1,464
Equity-based compensation – employees and non-employees	7,411		3,281
Provision for bad debts	810		11
Provision for inventory obsolescence	1,529		1,520
Revenue from receipt of equity	-12,680		-159
Realized gain on sale of equity securities	-10,953		0
Loss on conversion of 3.00% convertible senior notes	8,688		0
Loss on sale of property, plant and equipment	56		0
Change in fair value of derivatives instruments	38,691		-1,309
Change in fair value of contingent consideration	4,173		2,665
Deferred income tax benefit	-197		0
Changes in assets and liabilities of continuing operations, net of the effects of acquisitions:	'		'
Accounts receivable	-724		-184
Inventory	952		-4,443
Prepaid expenses and other current assets	-2,081		-1,312
Other assets	525		77
Accounts payable	2,303		-331
Foreign currency measurement	-1,409		-204
Accrued expenses	6,928		459
Cash used in operating activities of continuing operations	-32,142		-19,701
Cash used in operating activities of discontinued operations	0		14
Net cash used in operating activities	-32,142		-19,687
Cash flows from investing activities:	'		'
Investments in investees	-13,341		-2,700
Proceeds from sale of equity securities	11,628		0
Acquisition of businesses, net of cash	20,528		-10,512
Purchase of marketable securities	-50,027		-28,923
Maturities of short-term marketable securities	25,016		10,000
Proceeds from the sale of property, plant and equipment	631		0
Capital expenditures	-2,991		-1,064
Net cash used in investing activities	-8,556		-33,199
Cash flows from financing activities:	'		'
Issuance of 3.00% convertible senior notes, net, including related parties	170,184		0
Payment of Series D dividends, including related parties	-3,015		0
Proceeds from the exercise of Common Stock options and warrants	5,061		1,702
Borrowings on lines of credit	24,613		29,389
Repayments of lines of credit	-27,706		-26,108
Net cash provided by financing activities	169,137		4,983
Effect of exchange rate on cash and cash equivalents	34		-185
Net increase (decrease) in cash and cash equivalents	128,473		-48,088
Cash and cash equivalents at beginning of period	27,361	[1]	71,516
Cash and cash equivalents at end of period	155,834	[1]	23,428
SUPPLEMENTAL INFORMATION:	'		'
Interest paid	3,126		613
Income taxes paid, net	316		515
Revenue related to sale of intellectual property	12,500		0
Non-cash financing:	'		'
Series D Preferred Stock	24,386		0
3.00% convertible senior notes	'		0
Common Stock warrants, net exercised	815		7
PROLOR [Member]	'		'
Issuance of Common Stock to acquire:	'		'
Stock Issued	586,643		0
Cytochroma [Member]	'		'
Issuance of Common Stock to acquire:	'		'
Stock Issued	146,902		0
OPKO Brazil [Member]	'		'
Issuance of Common Stock to acquire:	'		'
Stock Issued	436		0
Farmadiet [Member]	'		'
Issuance of Common Stock to acquire:	'		'
Stock Issued	$4,404		$805
[1]	As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Condensed_Consolidated_Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	Sep. 30, 2013
Statement of Cash Flows [Abstract]	'
Convertible senior notes interest rate	3.00%

Business_and_Organization

Business and Organization	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
BUSINESS AND ORGANIZATION	'
	BUSINESS AND ORGANIZATION
	We are a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies. We are developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, laboratory developed tests, point-of-care tests, and proprietary pharmaceuticals and vaccines. We plan to commercialize these solutions on a global basis in large and high growth markets, including emerging markets.
	We own established pharmaceutical platforms in Spain, Chile and Mexico, which are generating revenue and which we expect to generate positive cash flow and facilitate future market entry for our products currently in development. In addition, we recently established pharmaceutical operations in Brazil. We also operate a specialty active pharmaceutical ingredients (“APIs”) manufacturer in Israel, which we expect to play a valuable role in the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products. We operate a laboratory business with laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), that has a strong presence in the U.S. urologic pathology market, and will provide us with a platform to commercialize certain of our novel diagnostics tests currently in development.
	We are incorporated in Delaware and our principal executive offices are located in leased offices in Miami, Florida. We lease office and lab space in Jupiter and Miramar, Florida, and Nes Ziona, Israel, which is where our molecular diagnostics research and development, oligonucleotide research and development and carboxyl terminal peptide research and development operations are based, respectively. We lease office, manufacturing and warehouse space in Woburn, Massachusetts for our point-of-care diagnostics business, and in Nesher, Israel for our API business. We lease laboratory and office space in Nashville, Tennessee and Burlingame, California for our CLIA-certified laboratory business, and we lease office space in Bannockburn, Illinois, and Markham, Ontario for our pharmaceutical business directed to chronic kidney disease. Our Chilean operations are located in leased offices and warehouse facilities in Santiago. Our Mexican operations are based in owned offices, an owned manufacturing facility and a leased warehouse facility in Guadalajara and in leased offices in Mexico City. Our Spanish operations are based in owned offices in Barcelona, in an owned manufacturing facility in Banyoles and a leased warehouse facility in Palol de Revardit. Our Brazilian operations are located in leased offices in Sao Paulo.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary to present fairly the Company’s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the three and nine months ended September 30, 2013, are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2013 or for future periods. The unaudited condensed consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012.
	Reclassifications and correction of an error. Certain prior year amounts in the condensed consolidated financial statements have been reclassified to conform with the 2013 presentation. Due to the acquisition of OPKO OURLab, LLC (formerly Prost-Data, Inc.), our CLIA certified laboratory business (“OURLab”) in December 2012, we changed our segment presentation to include diagnostics as a reportable segment. As a result of this change in reportable segments, we restated certain prior year amounts in the condensed consolidated financial statements to conform with the 2013 presentation. These reclassifications had no impact on our results of operations. Refer to Note 12.
	The condensed consolidated statements of operations for the three and nine months ended September 30, 2013 include a $2.7 million, or $0.01 per share, reduction of research and development expense. This reduction is the resulting of correcting the cumulative effect of an error in calculating equity based compensation expense for certain performance based stock options granted to a non-employee. The effect of this error was not material to the financial statements of any prior annual or quarterly periods nor is it material to 2013 financial statements presented herein; and as such, the cumulative effect of such error was recorded as a reduction to research and development expense in the three and nine months ended September 30, 2013.
	Principles of consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of OPKO Health, Inc., our wholly-owned subsidiaries and variable interest entities (“VIEs”) in which we are deemed to be the primary beneficiary. All significant intercompany accounts and transactions are eliminated in consolidation.
	Use of estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and cash equivalents. Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.
	Inventories. Inventories are valued at the lower of cost or market (net realizable value). Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost or market.
	Goodwill and Intangible Assets. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired when accounted for by the purchase method of accounting and arose from our acquisitions. Goodwill and other intangible assets acquired in business combinations, licensing and other transactions at September 30, 2013 and December 31, 2012 were $1.1 billion and $0.2 billion, respectively.
	Assets acquired and liabilities assumed in business combinations, licensing and other transactions are recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. We determined the fair value of intangible assets, including in-process research and development (“IPR&D”), using the “income method.”
	Goodwill is tested at least annually for impairment, or when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, on an enterprise level by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that its fair value exceeds the carrying value.
	Fair value measurements. The carrying amounts of our cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term maturities of these instruments. Investments that are considered available for sale as of September 30, 2013 are carried at fair value.
	Short-term investments, which we invest in from time to time, include bank deposits, corporate notes, U.S. treasury securities and U.S. government agency securities with original maturities of greater than 90 days and remaining maturities of less than one year. Long-term investments include corporate notes, U.S. treasury securities and U.S. government agency securities with maturities greater than one year.
	In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 8.
	Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as contingent consideration income. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.
	Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations, when they occur, the only exception being derivatives that qualify as hedges. For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2013 and December 31, 2012, our forward contracts for inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognize all changes in the fair values of our derivatives instruments in Fair value changes of derivatives instruments, net, in our Condensed Consolidated Statement of Operations. Refer to Note 9.
	Revenue recognition. Generally, we recognize revenue from product sales when goods are shipped and title and risk of loss transfer to our customers. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and management’s evaluation of specific factors that may increase or decrease the risk of product returns.
	Revenue for laboratory services are recognized on the accrual basis at the time test results are reported, which approximates when services are provided. Services are provided to certain patients covered by various third-party payer programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services under third-party payer programs are included in sales net of allowances for contractual discounts and allowances for differences between the amounts billed and estimated program payment amounts. Adjustments to the estimated payment amounts based on final settlement with the programs are recorded upon settlement as an adjustment to revenue. For the three and nine months ended September 30, 2013, revenue from services also includes $0.2 million and $0.6 million, respectively, of revenue related to our consulting agreement with Neovasc, Inc. (“Neovasc”) and to revenue related to molecular diagnostics collaboration agreements. For the three and nine months ended September 30, 2012, revenue from services included $0.1 million and $0.3 million, respectively, of revenue related to our consulting agreement with Neovasc and to revenue related to molecular diagnostics collaboration agreements. We recognize this revenue on a straight-line basis over the contractual term of the agreements.
	Revenue from transfer of intellectual property includes revenue related to the sale, license or transfer of intellectual property such as upfront license payments, license fees and milestone payments received through our license, collaboration and commercialization agreements. We analyze our multiple-element arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting.
	Non-refundable license fees for the out-license of our technology are recognized depending on the provisions of each agreement. We recognize non-refundable upfront license payments as revenue upon receipt if the license has standalone value and the fair value of our undelivered obligations, if any, can be determined. If the license is considered to have standalone value but the fair value of any of the undelivered items cannot be determined, the license payments are recognized as revenue over the period of our performance for such undelivered items or services. License fees with ongoing involvement or performance obligations are recorded as deferred revenue, included in Accrued expenses or Other long-term liabilities, when received and generally are recognized ratably over the period of such performance obligation only after both the license period has commenced and we have delivered the technology.
	The assessment of our obligations and related performance periods requires significant management judgment. If an agreement contains research and development obligations, the relevant time period for the research and development phase is based on management estimates and could vary depending on the outcome of clinical trials and the regulatory approval process. Such changes could materially impact the revenue recognized, and as a result, management reviews the estimates related to the relevant time period of research and development on a quarterly basis. For the nine months ended September 30, 2013, we recorded $16.1 million of revenue from the transfer of intellectual property, of which $12.5 million related to the sale of substantially all of our assets in the field of RNA interference to RXi Pharmaceuticals Corporation (“RXi”) and $3.2 million related to the rights granted to OAO Pharmsynthez ("Pharmsynthez") of certain technologies. Refer to Note 5.
	Revenue from milestone payments related to arrangements under which we have continuing performance obligations are recognized as Revenue from transfer of intellectual property upon achievement of the milestone only if all of the following conditions are met: the milestone payments are non-refundable; there was substantive uncertainty at the date of entering into the arrangement that the milestone would be achieved; the milestone is commensurate with either the vendor’s performance to achieve the milestone or the enhancement of the value of the delivered item by the vendor; the milestone relates solely to past performance; and the amount of the milestone is reasonable in relation to the effort expended or the risk associated with the achievement of the milestone. If any of these conditions are not met, the milestone payments are not considered to be substantive and are, therefore, deferred and recognized as Revenue from transfer of intellectual property over the term of the arrangement as we complete our performance obligations.
	Total deferred revenue included in Accrued expenses and Other long-term liabilities was $7.9 million and $1.9 million at September 30, 2013 and December 31, 2012, respectively.
	Allowance for doubtful accounts. We analyze accounts receivable and historical bad debt levels, customer credit worthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts using the specific identification method. Our reported net loss is directly affected by our estimate of the collectability of accounts receivable. The amount of the allowance for doubtful accounts was $1.1 million and $0.5 million at September 30, 2013 and December 31, 2012, respectively.
	Equity-based compensation. We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the statement of operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits, realized from the exercise of stock options as a financing cash inflow rather than as a reduction of taxes paid in cash flow from operations. Equity-based compensation arrangements to non-employees are recorded at their fair value on the measurement date. The measurement of equity-based compensation is subject to periodic adjustment as the underlying equity instruments vest. During the three months ended September 30, 2013 and 2012, we recorded $0.4 million and $1.1 million , respectively, of equity-based compensation expense. During the nine months ended September 30, 2013 and 2012, we recorded $7.4 million, and $3.3 million , respectively, of equity-based compensation expense.
	Research and development expenses. Research and development expenses include external and internal expenses, partially offset by third-party grants and fundings arising from collaboration agreements. External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and stock-based compensation expense. Other unallocated internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.
	Segment reporting. Our chief operating decision-maker (“CODM”) is comprised of our executive management with the oversight of our Board of Directors. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain and Brazil. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OURLab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
	Variable interest entities. The consolidation of VIEs is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 5.
	Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or investments available for sale based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations. Refer to Note 5. For investments classified as available for sale, we record changes in their fair value as unrealized gain or loss in Other comprehensive loss based on their closing price per share at the end of each reporting period. Refer to Note 5.
	Recent accounting pronouncements. In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-2, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, (“ASU 2013-2”). ASU 2013-2 requires the presentation of reclassifications out of accumulated other comprehensive income in either (1)the notes or (2)the face of the financial statements. We adopted ASU 2013-2 for our first quarter ended March 31, 2013. The adoption of ASU 2013-2 did not have a material impact in our condensed consolidated financial statements, but did require certain additional disclosures. Refer to Note 7.
	In July 2013, the FASB issued ASU 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11is intended to eliminate inconsistent practices regarding the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from the dis-allowance of a tax position. This ASU will be effective for our fiscal year beginning January 1, 2014 and subsequent interim periods. The adoption of ASU 2013-11 is not expected to have a material effect on our condensed consolidated financial statements.

Loss_Per_Share

Loss Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
LOSS PER SHARE	'
	LOSS PER SHARE
	Basic loss per share is computed by dividing our net loss by the weighted average number of shares outstanding during the period. Diluted loss per share is computed by dividing our net loss by the weighted average number of shares outstanding and the impact of all dilutive potential common shares, primarily stock options. The dilutive impact of common stock options and common stock warrants is determined by applying the “treasury stock” method. Potentially dilutive shares issuable pursuant to the Notes (defined in Note 6) were not included in the computation of net loss per share for the three and nine months ended September 30, 2013, because their inclusion would be anti-dilutive.
	Also, a total of 35,157,966 and 26,022,072 potential shares of Common Stock have been excluded from the calculation of diluted net loss per share for the three months ended September 30, 2013 and 2012, respectively, because their inclusion would be anti-dilutive. A total of 31,659,650 and 26,836,546 potential shares of Common Stock have been excluded from the calculation of net loss per share for the nine months ended September 30, 2013 and 2012, respectively, because their inclusion would be anti-dilutive.
	During the three months ended September 30, 2013, 3,206,230 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised and issued. During the three months ended September 30, 2012, 161,264 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 160,411 shares of Common Stock. Of the 161,264 Common Stock options and Common Stock warrants exercised, 853 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the warrant agreements.
	During the nine months ended September 30, 2013, 4,933,976 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 4,818,462 shares of Common Stock. Of the 4,933,976 Common Stock options and Common Stock warrants exercised, 115,514 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the warrant agreements. During nine months ended September 30, 2012, 750,162 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 748,783 shares of Common Stock. Of the 750,162 Common Stock options and Common Stock warrants exercised, 1,379 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the warrant agreements.

Composition_of_Certain_Financi

Composition of Certain Financial Statement Captions	9 Months Ended
	Sep. 30, 2013
Compositions of Certain Financial Statement Captions [Abstract]	'
COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS	'
	COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS
	(In thousands)	September 30,			December 31,
		2013			2012
	Accounts receivable, net:
	Accounts receivable	$	22,506		$	21,636
	Less: allowance for doubtful accounts	(1,134		)	(474		)
		$	21,372		$	21,162
	Inventories, net:
	Finished products	$	14,775		$	17,963
	Work in-process	1,450			688
	Raw materials	4,426			4,923
	Less: inventory reserve	(1,135		)	(1,313		)
		$	19,516		$	22,261
	Prepaid expenses and other current assets:
	Prepaid supplies	$	839		$	443
	Prepaid insurance	843			301
	Pharmsynthez Note Receivable and Purchase Option	6,755			—
	Other receivables	3,818			886
	Taxes recoverable	2,992			1,493
	Other	4,304			4,750
		$	19,551		$	7,873
	Intangible assets, net:
	Technologies	$	52,947		$	52,810
	Customer relationships	22,883			23,088
	Product registrations	9,861			9,637
	Tradenames	3,702			3,746
	Covenants not to compete	8,667			8,662
	Other	1,177			367
	Less:  accumulated amortization	(21,904		)	(14,072		)
		$	77,333		$	84,238
	Accrued expenses:
	Taxes payable	$	3,225		$	1,614
	Deferred revenue	7,040			1,518
	Clinical trials	3,543			50
	Professional fees	7,203			675
	Employee benefits	6,416			3,319
	Deferred acquisition payments, net of discount	5,335			6,172
	Contingent consideration	3,695			5,126
	Interest payable related to the Notes	925			—
	Other	5,887			6,182
		$	43,269		$	24,656
	(In thousands)	September 30,			December 31,
		2013			2012
	Other long-term liabilities:
	Contingent consideration – Cytochroma	$	51,447		$	—
	Contingent consideration – Farmadiet	542			532
	Contingent consideration – OPKO Diagnostics	12,976			11,310
	Contingent consideration – FineTech	—			2,578
	Contingent consideration – CURNA	549			510
	Deferred acquisition payments, net of discount	—			3,931
	Mortgages and other debts payable	3,350			5,150
	Deferred tax liabilities	164,892			9,777
	Other, including deferred revenue	1,006			380
		$	234,762		$	34,168
	The change in value of the intangible assets is primarily due to the acquisitions of Cytochroma Inc. (“Cytochroma”) PROLOR Biotech, Inc. ("PROLOR") and OPKO Do Brasil Comércio De Produtos Farmacéuticos Ltda ("OPKO Brazil"), previously known as Silcon Comércio, Importacao E Exportacao de Produtos Farmacéuticos e Cosmeticos Ltda, as well as the foreign currency fluctuations between the Chilean and Mexican pesos, the Brazilian Reals, the Euro and the Shekel against the U.S. dollar at September 30, 2013 and December 31, 2012.

Acquisitions_Investments_and_L

Acquisitions, Investments, and Licenses	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
ACQUISITIONS, INVESTMENTS, AND LICENSES	'
	ACQUISITIONS, INVESTMENTS AND LICENSES
	PROLOR acquisition
	In August 2013, we acquired PROLOR pursuant to an Agreement and Plan of Merger dated as of April 23, 2013 (the "PROLOR Merger Agreement") in an all-stock transaction. PROLOR is an Israeli-based biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins.
	Under the terms of the PROLOR Merger Agreement, holders of PROLOR common stock received 0.9951 shares of our Common Stock for each share of PROLOR common stock. At closing we delivered 63,670,805 shares of our Common Stock valued at $540.6 million based on the closing price per share of our Common Stock as reported by the NYSE on the closing date of the acquisition, or $8.49 per share. In addition, each outstanding option and warrant to purchase shares of PROLOR Common Stock that was outstanding and unexercised immediately prior to the closing date, whether vested or not vested, was converted into 7,889,265 options and warrants to purchase OPKO Common Stock at a fair value of $46.1 million.
	Until completion of the acquisition of PROLOR, Dr. Phillip Frost, our Chairman and Chief Executive Officer, was PROLOR’s Chairman of the Board and a greater than 5% stockholder of PROLOR. Dr. Jane H. Hsiao, our Vice Chairman and Chief Technology Officer and Mr. Steven Rubin, our Executive Vice President, Administration, were both directors of PROLOR and less than 5% stockholders of PROLOR.
	Cytochroma acquisition
	In March 2013, we acquired Cytochroma, a corporation located in Markham, Canada, whose lead products, both in Phase 3 development, are RayaldyTM, a vitamin D prohormone to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency, and AlpharenTM, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients (the “Cytochroma Acquisition”).
	In connection with the Cytochroma Acquisition, we delivered 20,517,030 of shares of our Common Stock valued at $146.9 million based on the closing price per share of our Common Stock as reported by the NYSE on the actual closing date of the acquisition, or $7.16 per share. The number of shares issued was based on the volume-weighted average price per share of our Common Stock as reported on the NYSE for the 10 trading days immediately preceding the date of the purchase agreement for the Cytochroma Acquisition, or $4.87 per share. The Cytochroma Agreement contains customary representations, warranties, conditions to closing, indemnification rights and obligations of the parties.
	In addition, the Cytochroma Acquisition requires payments of up to an additional $190.0 million in cash or additional shares of our Common Stock, at our election, upon the achievement of certain milestones relating to development and annual revenue. As a result, we recorded $47.7 million as contingent consideration. We evaluate the contingent consideration on an ongoing basis and the changes in the fair value are recognized in earnings until the milestones are achieved. Refer to Note 8.
	The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the acquisitions of Cytochroma and PROLOR at the dates of acquisition, which are subject to change while contingencies that existed on the acquisition date are resolved:
	(In thousands)	Cytochroma				PROLOR
	Current assets (1)	$	1,224			$	21,500
	Intangible assets:
	In-process research and development	191,530				590,200
	Patents	210				—
	Total intangible assets	191,740				590,200
	Goodwill	2,411				139,784
	Property, plant and equipment	306				1,057
	Other assets	—				371
	Accounts payable and accrued expenses	(1,069		)		(9,866		)
	Deferred tax liability	—				(156,403		)
	Total purchase price	$	194,612			$	586,643
	(1)Current assets include cash of $0.4 million and $20.5 million related to the Cytochroma and PROLOR acquisitions, respectively.
	Goodwill from the acquisition of PROLOR principally relates to the deferred tax liability generated as a result of this being a stock transaction and the assembled workforce. Goodwill from the acquisition of Cytochroma principally relates to the assembled workforce. Goodwill is not tax deductible for income tax purposes.
	OPKO Brazil asset acquisition
	In February 2013, we acquired the assets of OPKO Brazil, a Brazilian pharmaceutical company, pursuant to a purchase agreement entered into on December 26, 2012. Pursuant to the purchase agreement, we paid $0.3 million in cash and delivered 64,684 shares of our Common Stock at closing valued at $0.4 million based on the closing price per share of our Common Stock as reported by the NYSE on the actual closing date of the acquisition, or $6.73 per share. The number of shares issued was based on the average closing price per share of Common Stock as reported on the NYSE for the 10 trading days immediately preceding the execution of the purchase agreement, or $4.64 per share.
	We accounted for this acquisition as an asset acquisition rather than a business combination. As a result we recorded the assets at fair value, with most of the value being allocated to the most significant asset, its pharmaceutical business licenses.
	OURLab acquisition
	In October 2012, we entered into a definitive merger agreement to acquire OURLab, a Nashville-based CLIA laboratory. In December 2012, we paid $9.4 million in cash and delivered 7,072,748 shares of our Common Stock at closing valued of $32.9 million based on the closing sales price per share of our Common Stock as reported by the NYSE on the actual closing date of the acquisition, or $4.65 per share. The number of shares issued was based on the average closing price per share of our Common Stock as reported on the NYSE for the 15 trading days immediately preceding the execution of the purchase agreement, or $4.33 per share. Pursuant to the merger agreement, 1,732,102 shares of Common Stock issued in the transaction are being held in a separate escrow account to secure indemnification obligations of the OURLab seller.
	Farmadiet acquisition
	In August 2012, we entered into a stock purchase agreement pursuant to which we acquired all of the outstanding stock of Farmadiet Group Holding, S.L. (“Farmadiet”), a Spanish company engaged in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products in Europe (the “Farmadiet Transaction”).
	In connection with the Farmadiet Transaction, we agreed to pay an aggregate purchase price of €13.5 million (approximately $16.0 million), of which (i) 50% ($8.4 million) was paid in cash at closing, and (ii) 50% (the “Deferred Payments”) will be paid, at our option, in cash or shares of our Common Stock as follows: (x) 25% to be paid on the first anniversary of the closing date; and (y) 25% to be paid 18 months after the closing date. On the date of acquisition, we recorded the €6.8 million Deferred Payments at $7.8 million, net of a discount of $0.6 million. The discount will be amortized as interest expense through the respective payment dates. The Deferred Payments are required to be paid in Euro and as such, the final U.S. dollar amount to be paid will be based on the exchange rate at the time the Deferred Payments are made. In the event we elect to pay the Deferred Payments in shares of our Common Stock, the number of shares issuable shall be calculated using the average closing price per share of our Common Stock as reported on the NYSE for the 10 trading days immediately preceding the applicable payment date. On August 2, 2013, we issued 585,703 shares of our Common Stock, in accordance with the first Deferred Payment. The number of shares issued was based on the average closing price per share of our Common Stock as reported on the NYSE for the 10 trading days up to and including August 1, 2013, or $7.61 per share. We have the right to hold back up to €2.8 million (approximately $3.6 million as of September 30, 2013) from the Deferred Payment to satisfy indemnity claims.
	In connection with the Farmadiet Transaction, we also entered into two ancillary transactions (the “Ancillary Transactions”). In exchange for a 40% interest held by one of the sellers in one of Farmadiet’s subsidiaries, we agreed to issue up to an aggregate of 250,000 shares of our Common Stock, of which (a) 125,000 shares were issued on the closing date, and (b) 125,000 will be issued upon achieving certain milestones. In addition, we acquired an interest held by an affiliate of Farmadiet in a product in development in exchange for which we agreed to pay up to an aggregate of €1.0 million ($1.3 million) payable at our option in cash or shares of our Common Stock, of which (a) 25% ($0.3 million) was paid at closing through delivery of 70,421 shares of our Common Stock, and 75% ($1.0 million) will be paid in cash or shares of our Common Stock upon achieving certain milestones. As a result, we recorded $1.2 million as contingent consideration for the future consideration. We evaluate the contingent consideration on an ongoing basis and the changes in fair value are recognized in earnings until the milestones are achieved. Refer to Note 8. The final U.S. dollar amount to be paid will be based on the exchange rate at the time the milestones are achieved. The number of shares of our Common Stock issued is determined based on the average closing sales price for our Common Stock on the NYSE for the 10 trading days preceding the required payment date.
	ALS acquisition
	In April 2012, we completed the acquisition of ALS Distribuidora Limitada (“ALS”), a privately-held Chilean pharmaceutical company, pursuant to a stock purchase agreement entered into in January 2012. In connection with the transaction, we agreed to pay up to a total of $4.0 million in cash to the sellers. Pursuant to the purchase agreement, we paid (i) $2.4 million in cash at the closing, less certain liabilities, and (ii) $0.8 million in cash at the closing into a separate escrow account to satisfy possible indemnity claims. During the nine months ended September 30, 2013, we paid the remaining $0.8 million that we had agreed to pay upon the legal registration in the name of ALS of certain trademarks and product registrations previously held by the former owner of ALS, Arama Laboratorios y Compañía Limitada.
	Pro forma disclosure for acquisitions
	The following table includes the pro forma results for the three and nine months ended September 30, 2013 and 2012 of the combined companies as though the acquisition of Cytochroma and PROLOR had been completed as of the beginning of each period, respectively.
		For the three months ended September 30,							For the nine months ended September 30,
	(In thousands)	2013				2012			2013			2012
	Revenues	$	20,641			$	13,976		$	75,838		$	37,327
	Net loss	$	(75,858	)		$	(15,745	)	$	130,118		$	(43,864	)
	Net loss attributable to common shareholders	$	(75,055	)		$	(16,302	)	$	(128,229	)	$	(45,534	)
	Basic and diluted loss per share	$	(0.19	)		$	(0.04	)	$	(0.32	)	$	(0.12	)
	The unaudited pro forma financial information is presented for information purposes only. The unaudited pro forma financial information may not necessarily reflect our future results of operations or what the results of operations would have been had we owned and operated each company as of the beginning of the period presented.
	We incurred a pre-tax loss related to the activities of Cytochroma and PROLOR of $15.6 million and $2.5 million, respectively, from the date of our acquisitions through September 30, 2013.
	Investments
	The total assets, liabilities, and net losses of our equity method investees as of and for the nine months ended September 30, 2013 were $105.5 million, $39.6 million, and $51.2 million, respectively. The following table reflects our maximum exposure, accounting method, ownership interest and underlying equity in net assets of each of our unconsolidated investments as of September 30, 2013:
	(Dollars in thousands, except per share prices)		Year		Accounting method		Ownership at		Investment			Underlying equity in net assets			Closing share price
	Investee name		invested				September 30,								at September 30, 2013
							2013								for investments
															available for sale
	Sorrento		2009		Equity method		14	%	$	2,300		$	821
	Cocrystal		2009		Equity method		16	%	2,500			358
	Neovasc		2011		Equity method		6	%	3,798			454
	Fabrus		2010		VIE, equity method		13	%	650			(108		)
	BZNE common stock		2012		VIE, equity method		11	%	1,276			(1,184		)
	RXi		2013		Equity method		19	%	15,000			2,847
	Pharmsynthez		2013		Equity method		11	%	5,036			5,156
	TESARO		2010		Investment available for sale		1	%	56							$	38.74
	Neovasc options		2011		Investment available for sale		N/A		925						CA	$	2.35
	BZNE Note and conversion feature		2012		VIE, investment available for sale		N/A		1,700
	ChromaDex		2012		Investment available for sale		1	%	1,320							$	0.81
	Plus unrealized/realized gains on investments, options and warrants, net								2,708
Less accumulated losses in investees								(12,579		)
Total carrying value of equity method investees and investments, available for sale								$	24,690
Neovasc
In 2011, we made an investment in Neovasc, a medical technology company based in Vancouver, Canada. We invested $2.0 million and received two million Neovasc common shares, and two-year warrants to purchase an additional one million shares for $1.25 a share. During the nine months ended September 30, 2013 we exercised the warrants and paid $1.2 million. We accounted for the warrants as an investment, available for sale and recorded the warrants at fair value on the date of acquisition. We recorded the changes in the fair value of the warrants in Fair value changes of derivatives instruments, net in our Condensed Consolidated Statements of Operations.
2013 licensing agreements
An element of our growth strategy is to leverage our proprietary technology through a combination of internal development, acquisition, and external partnerships to maximize the commercial opportunities for our portfolio of proprietary pharmaceutical and diagnostic products and as such during 2013, we have entered into licensing agreements with Pharmsynthez and RXi.
Pharmsynthez transactions
In April 2013, we entered into a series of concurrent transactions with Pharmsynthez, a Russian pharmaceutical company traded on the Moscow Stock Exchange. The transactions consisted of:
•We delivered approximately $9.6 million to Pharmsynthez.
•Pharmsynthez issued to us approximately 13.6 million of its common shares.
•Pharmsynthez agreed, at its option, to issue approximately 12.0 million common shares to us or to pay us Russian Rubles (“RUR”) 265.0 million ($8.1 million) on or before December 31, 2013 (the "Pharmsynthez Note Receivable").
• We have a right to purchase additional shares in Pharmsynthez at a fixed price if Pharmsynthez pays us in cash rather than delivering to us the 12.0 million Pharmsynthez common shares (the “Purchase Option”).
• We granted rights to certain technologies in the Russian Federation, Ukraine, Belorussia, Azerbaidjan and Kazakhstan (the “Territories”) to Pharmsynthez.
•We will receive from Pharmsynthez royalty on net sales of products incorporating the technologies in the Territories, as well as a percentage of any sublicense income from third parties for the technologies in the Territories.
•Pharmsynthez will pay us $9.5 million under the various collaboration and funding agreements for the development of the technologies (the “Collaboration Payments”).
We recorded the initial shares received in Pharmsynthez as an equity method investment.  We recorded the Pharmsynthez Note Receivable, and the Purchase Option, as financial instruments and elected the fair value option for subsequent measurement. Changes in the fair value of the receivable from Pharmsynthez for its common stock or RUR, with the embedded derivative, and the Purchase Option are recorded in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2013.
We have accounted for the license and development activities as a multi-element arrangement, and allocated the total arrangement consideration based on the relative selling prices of the elements. We will record the allocated consideration for development activities as an offset to Research and development expenses over the three-year term of the Collaboration Payments.  We will record revenue in connection with the grant of rights to the technologies proportionately as the payments are received.
During the three and nine months ended September 30, 2013, no payments were received for the Pharmsynthez Notes Receivable. During the three and nine months ended September 30, 2013, we received $3.4 million and $6.8 million, respectively, related to the Collaboration Payments of which we recorded $1.3 million and $3.2 million, respectively, in Revenue from transfer of intellectual property and $0.4 million and $0.7 million, respectively, as an offset to Research and development expenses.
RXi transactions
In March 2013, we completed the sale to RXi of substantially all of our assets in the field of RNA interference (the “RNAi Assets”) (collectively, the “Asset Purchase Agreement”). As consideration for the RNAi Assets, at the closing of the Asset Purchase Agreement, RXi issued to us 50 million shares of its common stock (the “APA Shares”). In accounting for the sale of the RNAi Assets, we determined that we did not have any continuing involvement in the development of the RNAi Assets or any other future performance obligations and, as a result, during the nine months ended September 30, 2013, we recognized the APA Shares as $12.5 million of revenue from transfer of intellectual property in our Condensed Consolidated Statement of Operations.
Pursuant to the Asset Purchase Agreement, RXi will be required to pay us up to $50.0 million in milestone payments upon the successful development and commercialization of each drug developed by RXi, certain of its affiliates or any of its or their licensees or sublicensees utilizing patents included within the RNAi Assets (each, a “Qualified Drug”). In addition, RXi will also be required to pay us royalties equal to: (a) a mid single-digit percentage of “Net Sales” (as defined in the Asset Purchase Agreement) with respect to each Qualified Drug sold for an ophthalmologic use during the applicable “Royalty Period” (as defined in the Asset Purchase Agreement); and (b) a low single-digit percentage of net sales with respect to each Qualified Drug sold for a non-ophthalmologic use during the applicable royalty period.
In addition to the Asset Purchase Agreement, we purchased 17,241,380 shares of RXi, for $2.5 million, as part of a $16.4 million financing for RXi, which included other related parties. We have determined that our ownership, along with that of our related parties, provides us the ability to exercise significant influence over RXi operations and as such we have accounted for our investment in RXi under the equity method.
Investments in variable interest entities
We have determined that we hold variable interests in Fabrus, Inc. (“Fabrus”), Biozone Pharmaceutical, Inc. (“BZNE”) and SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd. We made this determination as a result of our assessment that they do not have sufficient resources to carry out their principal activities without additional financial support.
In order to determine the primary beneficiary of BZNE, we evaluated our investment and our related parties’ investments, as well as our investment combined with the related party group’s investments to identify if we had the power to direct the activities that most significantly impact the economic performance of BZNE. We determined that power to direct the activities that most significantly impact BZNE’s economic performance is conveyed through the board of directors of BZNE and no entity is able to appoint the BZNE governing body that oversees its executive management team. Based on the capital structure, governing documents and overall business operations of BZNE, we determined that, while a VIE, no single entity has the power to direct the activities that most significantly impact BZNE’s economic performance. However, we determined that we and our related parties can significantly influence the success of BZNE through our voting power. As such, we account for investment in BZNE under the equity method.
In order to determine the primary beneficiary of Fabrus, we evaluated our investment and our related parties’ investment, as well as our investment combined with the related party group’s investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Fabrus. We determined that power to direct the activities that most significantly impact Fabrus’s economic performance is conveyed through the board of directors of Fabrus as no entity is able to appoint the Fabrus governing body that oversees its executive management team. Based on the capital structure, governing documents and overall business operations of Fabrus, we determined that, while a VIE, no single entity has the power to direct the activities that most significantly impact Fabrus’s economic performance. We did determine, however, that our related parties can significantly influence the success of Fabrus through our board representation and voting power. Accordingly, as we and our related parties have the ability to exercise significant influence over Fabrus’ operations, we account for our investment in Fabrus under the equity method.
Consolidated variable interest entities
In June 2012, we entered into a share and debt purchase agreement whereby in exchange for $0.7 million we acquired shares representing a 45% stock ownership in SciVac from FDS Pharma LLP (“FDS”). SciVac is a privately-held Israeli company that produces a third-generation hepatitis B-vaccine. In November 2012 and during the nine months ended September 30, 2013, we loaned to SciVac a combined $1.8 million for working capital purposes. We have determined that we hold variable interests in SciVac based on our assessment that SciVac does not have sufficient resources to carry out its principal activities without financial support. In order to determine the fair market value of our investment in SciVac, we have utilized a business enterprise valuation approach.
In order to determine the primary beneficiary of SciVac, we evaluated our investment to identify if we had the power to direct the activities that most significantly impact the economic performance of SciVac. We have determined that the power to direct the activities that most significantly impact the economic performance of SciVac is conveyed through SciVac’s board of directors. SciVac’s board of directors appoint and oversee SciVac’s management team who carry out the activities that most significantly impact the economic performance of SciVac. As part of the share and debt purchase agreement, SciVac’s board of directors is constituted by 5 members, of which 3 members will be appointed by us, representing 60% of SciVac’s board. Based on this analysis, we determined that we have the power to direct the activities of SciVac and as such we are the primary beneficiary. As a result of this conclusion, we have consolidated the results of operations and financial position of SciVac and recorded a reduction of equity for the portion of SciVac we do not own.
The following table represents the consolidated assets and non-recourse liabilities related to SciVac as of September 30, 2013 and December 31, 2012. These assets are owned by, and these liabilities are obligations of, SciVac, not us.
(In thousands)	September 30,				December 31,
	2013				2012
Assets
Current assets:
Cash and cash equivalents	$	136			$	174
Accounts receivable, net	205				387
Inventories, net	1,653				1,092
Prepaid expenses and other current assets	185				199
Total current assets	2,179				1,852
Property, plant and equipment, net	1,410				1,539
Intangible assets, net	1,122				1,154
Goodwill	841				796
Other assets	312				231
Total assets	$	5,864			$	5,572
Liabilities
Current liabilities:
Accounts payable	$	1,129			$	1,108
Accrued expenses	5,969				2,859
Notes payable	1,284				—
Total current liabilities	8,382				3,967
Other long-term liabilities	279				1,529
Total liabilities	$	8,661			$	5,496

Debt

Debt	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
DEBT	'
	DEBT
	The following table sets forth information related to the 3.00% convertible senior notes which is included our Condensed Consolidated Balance Sheets:
	(In thousands)	Embedded conversion option			Convertible Notes			Discount			Total
	Balance at December 31, 2012	$	—		$	—		$	—		$	—
	Issuance of 3.00% convertible notes	59,204			175,000			(59,204		)	175,000
	Amortization of debt discount	—			—			4,866			4,866
	Debt discount write-off associated with conversion	—			—			5,368			5,368
	of debt
	Change in fair value of embedded derivative	41,818			—			—			41,818
	Conversion	(1,199		)	(16,936		)	—			(18,135		)
	Balance at September 30, 2013	$	99,823		$	158,064		$	(48,970	)	$	208,917
	In January 2013, we entered into note purchase agreements (the “Notes”) with qualified institutional buyers and accredited investors (collectively the “Purchaser”) in a private placement in reliance on exemptions from registration under the Securities Act of 1933, (the “Securities Act”). The Purchasers of the Notes include Frost Gamma Investments Trust, a trust affiliated with Dr. Frost, and Hsu Gamma Investment, L.P., an entity affiliated with Dr. Hsiao. The Notes were issued on January 30, 2013. The Notes, which total $175.0 million, bear interest at the rate of 3.00% per year, payable semiannually on February 1 and August 1 of each year, beginning August 1, 2013. The Notes will mature on February 1, 2033, unless earlier repurchased, redeemed or converted. Upon a fundamental change as defined in the instruments governing the Notes, subject to certain exceptions, the holders may require us to repurchase all or any portion of their Notes for cash at a repurchase price equal to 100% of the principal amount of the Notes being repurchased, plus any accrued and unpaid interest to but not including the fundamental change repurchase date.
	The Notes will be convertible at any time on or after November 1, 2032, through the second scheduled trading day immediately preceding the maturity date, at the option of the holders. Additionally, holders may convert their Notes prior to the close of business on the scheduled trading day immediately preceding November 1, 2032, under the following circumstances: (1) conversion based upon satisfaction of the trading price condition relating to the Notes; (2) conversion based on the Common Stock price; (3) conversion based upon the occurrence of specified corporate events; or (4) if we call the Notes for redemption. The Notes will be convertible into cash, shares of our Common Stock, or a combination of cash and shares of Common Stock, at our election unless we have made an irrevocable election of net share settlement. The initial conversion rate for the Notes will be 141.4827 shares of Common Stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $7.07 per share of Common Stock), and will be subject to adjustment upon the occurrence of certain events. In addition, we will, in certain circumstances, increase the conversion rate for holders who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture) and holders who convert upon the occurrence of certain specific events prior to February 1, 2017 (other than in connection with a make-whole fundamental change).
	On August 30, 2013, one of the conversion rights of the Notes was triggered. As a result, holders of the Notes converted $16.9 million principal amount into 2,396,145 shares of our Common Stock at a rate of 141.4827 shares of Common Stock per $1,000 principal amount of Notes. We recorded an $8.7 million loss on early conversion of the Notes in Other income (expense), net in our Condensed Consolidated Statement of Operations. The Notes were convertible through September 6, 2013 and may be convertible thereafter, if one or more of the conversion conditions are satisfied.
	We may not redeem the Notes prior to February 1, 2017. On or after February 1, 2017 and before February 1, 2019, we may redeem for cash any or all of the Notes but only if the last reported sale price of our Common Stock exceeds 130% of the applicable conversion price for at least 20 trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date on which we deliver the redemption notice. The redemption price will equal 100% of the principal amount of the Notes to be redeemed, plus any accrued and unpaid interest to but not including the redemption date. On or after February 1, 2019, we may redeem for cash any or all of the Notes at a redemption price of 100% of the principal amount of the Notes to be redeemed, plus any accrued and unpaid interest up to but not including the redemption date.
	The terms of the Notes, include, among others: (i) rights to convert into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the Notes on or after February 1, 2017 but prior to February 1, 2019. We have determined that these specific terms are considered to be embedded derivatives. As a result, embedded derivatives are required to be separated from the host contract, the Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. We have concluded that the embedded derivatives within the Notes meet these criteria and, as such, must be valued separate and apart from the Notes and recorded at fair value each reporting period.
	For purposes of accounting and financial reporting, we combine these embedded derivatives and value them together as one unit of accounting. At each reporting period, we record these embedded derivatives at fair value which is included as a component of the Notes on our Condensed Consolidated Balance Sheets.
	We have used a binomial lattice model in order to estimate the fair value of the embedded derivative in the Notes. A binomial lattice model generates two probable outcomes — one up and another down —arising at each point in time, starting from the date of valuation until the maturity date. A lattice was initially used to determine if the Notes would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the Notes will be converted early if the conversion value is greater than the holding value; or (ii) the Notes will be called if the holding value is greater than both (a) the redemption price (as defined in the Indenture) and (b) the conversion value plus the coupon make-whole payment at the time. If the Notes are called, then the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the Notes.
	Using this lattice, we valued the embedded derivatives using the “with-and-without method,” where the value of the Notes including the embedded derivatives is defined as the “with,” and the value of the Notes excluding the embedded derivatives is defined as the “without.” This method estimates the value of the embedded derivatives by looking at the difference in the values between the Notes with the embedded derivatives and the value of the Notes without the embedded derivatives.
	The lattice model requires the following inputs: (i) price of our Common Stock; (ii) Conversion Rate (as defined in the Indenture); (iii) Conversion Price (as defined in the Indenture); (iv) maturity date; (v) risk-free interest rate; (vi) estimated stock volatility; and (vii) estimated credit spread for the Company.
	The following table sets forth the inputs to the lattice model used to value the embedded derivative:
		September 30, 2013			Issuance Date
	Stock price	$	8.81		$	6.2
	Conversion Rate	141.4827			141.4827
	Conversion Price	$	7.07		$	7.07
	Maturity date	February 1, 2033			February 1, 2033
	Risk-free interest rate	1.5		%	1.12		%
	Estimated stock volatility	40		%	40		%
	Estimated credit spread	948 basis points			944 basis points
	The following table sets forth the fair value of the Notes with and without the embedded derivatives, and the fair value of the embedded derivatives as of the issuance date and September 30, 2013. At September 30, 2013 and at issuance date the principal amount of the Notes was $158.1 million and $175.0 million, respectively:
	(In thousands)	September 30, 2013			Issuance Date
	Fair value of Notes:
	With the embedded derivatives	$	210,105		$	175,000
	Without the embedded derivatives	$	110,282		$	115,796
	Estimated fair value of the embedded derivatives	$	99,823		$	59,204
	Changes in certain inputs into the lattice model can have a significant impact on changes in the estimated fair value of the embedded derivatives. For example, a decrease in our estimated credit spread results in an increase in the estimated value of the embedded derivatives. Conversely, a decrease in the price of our Common Stock results in a decrease in the estimated fair value of the embedded derivatives. From the date the Notes were issued through September 30, 2013, we observed an increase in the market price of our Common Stock which primarily resulted in a $41.8 million increase in the estimated fair value of our embedded derivatives recorded in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations.
	We have entered into line of credit agreements with fifteen financial institutions in Chile and Spain. These lines of credit are used primarily as a source of working capital for inventory purchases.
	The following table summarizes the amounts outstanding under the lines of credit:
	(Dollars in thousands)							Balance Outstanding
	Lender		Interest rate on		Credit line			September 30,			December 31,
			borrowings		capacity			2013			2012
	Itau Bank		8.04	%	$	3,000		$	2,207		$	2,738
	Bank of Chile		7.8	%	3,000			1,967			2,292
	BICE Bank		5.5	%	1,500			867			2,451
	Corp Banca		5.5	%	—			28			1,248
	BBVA Bank		8.29	%	2,500			1,230			2,823
	Penta Bank		9.48	%	800			992			833
	Security Bank		7.56	%	1,500			1,063			—
	BCI		5.5	%	1,000			1,216			—
	Estado Bank		6.88	%	2,000			1,732			1,963
	Sabadell Bank		7.6	%	203			—			3
	Bilbao Vizcaya Bank		4.9	%	406			91			377
	Banco Popular		8.25	%	406			—			260
	Santander Bank		6	%	203			—			—
	Banesto		5.8	%	203			4			163
	Banca March		6.25	%	270			—			44
	Total				$	16,991		$	11,397		$	15,195
	At September 30, 2013 and December 31, 2012, the weighted average interest rate on our lines of credit was approximately 7.4% and 6.5%, respectively.
	At September 30, 2013 and December 31, 2012, we had mortgage notes and other debt payables related to Farmadiet as follows:
	(In thousands)	September 30,			December 31,
		2013			2012
	Current portion of lines of credit and notes payable	$	1,796		$	2,331
	Other long-term liabilities	3,350			3,916
Total mortgage notes and other debt payables	$	5,146		$	6,247
The mortgages and other debts payable mature at various dates ranging from 2015 through 2024 bearing variable interest rates from 2.7% up to 6.3%. The weighted average interest rate on the mortgage notes and other debt payable at September 30, 2013 and December 31, 2012, was 4.2% and 4.5%, respectively.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
ACCUMULATED OTHER COMPREHENSIVE INCOME	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME
	For the nine months ended September 30, 2013, changes in Accumulated other comprehensive income, net of tax, were as follows:
	(In thousands)	Foreign			Unrealized
		currency			gains in
					Accumulated
					OCI
	Balance at December 31, 2012	$	3,196		$	4,160
	Other comprehensive income before reclassifications, net of tax (1)	(1,395		)	1,869
	Amounts reclassified from accumulated other comprehensive income, net of tax (1)	—			(4,593		)
	Net other comprehensive income	(1,395		)	(2,724		)
	Balance at September 30, 2013	$	1,801		$	1,436
	-1	Effective tax rate of 38.47%.
	Amounts reclassified from Accumulated other comprehensive income for the nine months ended September 30, 2013 related to $10.8 million realized gain on the sales of certain of our investments available for sale. Of the $10.8 million gain on the sales of our investments available for sale, a $7.5 million gain was reclassified from unrealized gains in Accumulated other comprehensive income to Other income (expense), net for the nine months ended September 30, 2013.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	FAIR VALUE MEASUREMENTS
	We record fair value at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
	A summary of our investments as of September 30, 2013, classified as available for sale, and carried at fair value is as follows:
		As of September 30, 2013
	(In thousands)	Amortized			Gross			Gross			Gain/(Loss)			Fair
		Cost			unrealized			unrealized			in			value
					gains in			losses in			Accumulated
					Accumulated			Accumulated			Deficit
					OCI			OCI
	Common stock investments, available for sale	$	1,376		$	1,417		$	—		$	—		$	2,793
	BZNE Note and conversion feature	1,700			53			—			287			2,040
	Neovasc common stock options	925			714			(202		)	181			1,618
	U.S. Treasury securities	25,004			—			—			—			25,004
	Total assets	$	29,005		$	2,184		$	(202	)	$	468		$	31,455
	A summary of our investments as of December 31, 2012, classified as available for sale, and carried at fair value is as follows:
		As of December 31, 2012
	(In thousands)	Amortized			Gross			Gross			Gain/(Loss)			Fair
		Cost			unrealized			unrealized			in			value
					gains in			losses in			Accumulated
					Accumulated			Accumulated			Deficit
					OCI			OCI
	Common stock investments, available for sale	$	2,051		$	6,185		$	—		$	—		$	8,236
	BZNE Note and conversion feature	1,700			53			—			287			2,040
	Neovasc common stock options	925			293			—			176			1,394
	Neovasc common stock warrants	659			194			—			(375		)	478
	Total assets	$	5,335		$	6,725		$	—		$	88		$	12,148
	Any future fluctuation in fair value related to these instruments that is judged to be temporary, including any recoveries of previous write-downs, will be recorded in Accumulated other comprehensive income or loss. If we determine that any future valuation adjustment was other-than-temporary, we will record a loss during the period such determination is made.
	As of September 30, 2013, we have money market funds that qualify as cash equivalents, forward contracts for inventory purchases (Refer to Note 9) and contingent consideration related to the acquisitions of CURNA, Inc. (“CURNA”), Claros Diagnostics, Inc. (“OPKO Diagnostics”), FineTech Pharmaceuticals, Ltd. (“FineTech”), Farmadiet, and Cytochroma that are required to be measured at fair value on a recurring basis. In addition, in connection with our investment and our consulting agreement with Neovasc, we record the related Neovasc options and warrants at fair value as well as the derivative instruments related to our transactions with Pharmsynthez.
	Our financial assets and liabilities measured at fair value on a recurring basis are as follows:
		Fair value measurements as of September 30, 2013
	(In thousands)	Quoted			Significant			Significant			Total
		prices in			other			unobservable
		active			observable			inputs
		markets for			inputs			(Level 3)
		identical			(Level 2)
		assets
		(Level 1)
	Assets:
	Money market funds	$	116,477		$	—		$	—		$	116,477
	U.S. Treasury securities	—			25,004			—			25,004
	Certificates of deposit	—			827			—			827
	Pharmsynthez Note Receivable and Purchase Option	—			6,755			—			6,755
	Common stock investments, available for sale	2,793			—			—			2,793
	BZNE Note and conversation feature	—			—			2,040			2,040
	Neovasc common stock options	—			1,618			—			1,618
	Total assets	$	119,270		$	34,204		$	2,040		$	155,514
	Liabilities:
	Forward contracts	$	—		$	(25	)	$	—		$	(25	)
	Embedded conversion option	—			—			99,823			99,823
	Deferred acquisition payments, net of discount	—			—			5,335			5,335
	Contingent consideration:
	CURNA	—			—			549			549
	OPKO Diagnostics	—			—			12,976			12,976
	FineTech	—			—			2,862			2,862
	Cytochroma	—			—			51,447			51,447
	Farmadiet	—			—			1,375			1,375
	Total liabilities	$	—		$	(25	)	$	174,367		$	174,342
		Fair value measurements as of December 31, 2012
	(In thousands)	Quoted			Significant			Significant			Total
		prices in			other			unobservable
		active			observable			inputs
		markets for			inputs			(Level 3)
		identical			(Level 2)
assets
(Level 1)
Assets:
Money market funds	$	18,716		$	—		$	—		$	18,716
Certificates of deposit	—			820			—			820
Common stock investments, available for sale	8,236			—			—			8,236
BZNE Note and conversation feature	—			—			2,040			2,040
Neovasc common stock options	—			1,394			—			1,394
Neovasc common stock warrants	—			478			—			478
Total assets	$	26,952		$	2,692		$	2,040		$	31,684
Liabilities:
Forward contracts	$	—		$	10		$	—		$	10
Deferred acquisition payments, net of discount	—			—			10,103			10,103
Contingent consideration:
CURNA	—			—			510			510
OPKO Diagnostics	—			—			12,974			12,974
FineTech	—			—			5,262			5,262
Farmadiet	—			—			1,310			1,310
Total liabilities	$	—		$	10		$	30,159		$	30,169
Our U.S. Treasury securities matured on October 15, 2013 ($25.0 million).
The carrying amount and estimated fair value of our long-term debt, as well as the applicable fair value hierarchy tiers, are contained in the table below. The fair value of the Notes is determined using a binomial lattice approach in order to estimate the fair value of the embedded derivative in the Notes. Refer to Note 6.
	September 30, 2013
(In thousands)	Carrying			Total			Level 1			Level 2			Level 3
	Value			Fair Value
Notes	$	109,094		$	110,282		$	—		$	—		$	110,282
As of September 30, 2013 and December 31, 2012, the carrying value of our other assets and liabilities approximates their fair value due to their short-term nature.
The following tables reconcile the beginning and ending balances of our Level 3 assets and liabilities as of September 30, 2013 and December 31, 2012:
	September 30, 2013
(In thousands)	BZNE Note			Contingent			Deferred			Embedded
	and			consideration			acquisition			conversion
	conversion						payments, net			option
	feature						of discount
Balance at December 31, 2012	$	2,040		$	20,056		$	10,103		$	—
Additions	—			47,710			—			59,204
Total losses (gains) for the period:
Included in results of operations	—			4,204			597			41,818
Conversion of the Notes	—			—			—			(1,199		)
Payments	—			(2,761		)	(5,365		)	—
Balance at September 30, 2013	$	2,040		$	69,209		$	5,335		$	99,823
	December 31, 2012
(In thousands)	BZNE Note			Contingent			Deferred
	and			consideration			acquisition
	conversion						payments, net
	feature						of discount
Balance at December 31, 2011	$	—		$	18,002		$	—
Additions	1,700			1,234			9,673
Total losses (gains) for the period:
Included in results of operations	1,563			820			430
Included in Other comprehensive loss	53			—			—
Transfer out to equity method investment	(1,276		)	—			—
Balance at December 31, 2012	$	2,040		$	20,056		$	10,103
The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies. We use the following methods and assumptions in estimating fair value:
BZNE Notes and conversion feature - The stock market activity in BZNE does not represent an active market and as such, we determined the fair market value utilizing a business enterprise valuation approach in order to determine the fair value of our investment. The most significant assumptions are the projected revenue growth and operating income (loss). The impact of a change in any of our significant underlying assumptions +/-1% would not result in a materially different fair value.
Contingent consideration – We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues. We use several discount rates depending on each type of contingent consideration related to FineTech, OPKO Diagnostics, CURNA, Farmadiet and Cytochroma transactions. The discount rates used range from 6% to 27% and were based on the weighted average cost of capital for those businesses. If the discount rates were to increase by 1%, on each transaction, the contingent consideration would decrease by $2.0 million. If estimated future sales were to decrease by 10%, the contingent consideration related to CURNA, FineTech and Cytochroma would decrease by $0.8 million. As of September 30, 2013, of the $69.2 million of contingent consideration, $3.7 million is recorded in Accrued expenses and $65.5 million is recorded in Other long-term liabilities. As of December 31, 2012, of the $20.0 million of contingent consideration, $5.1 million is recorded in Accrued expenses and $14.9 million is recorded in Other long-term liabilities.
Deferred payments – We estimate the fair value of the deferred payments utilizing a discounted cash flow model for the expected payments.
Embedded conversion option – We estimate the fair value of the embedded conversion option related to the Notes using a binomial lattice model. Refer to Note 6 for detail description of the binomial lattice model and the fair value assumptions used.
Pharmsynthez Note Receivable and Purchase Option - We determined the fair value of the Pharmsynthez Note Receivable and Purchase Option using a number of Black-Scholes scenarios simulating changes in Pharmsynthez's common stock price.

Derivative_Contracts

Derivative Contracts	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
DERIVATIVE CONTRACTS	'
	DERIVATIVE CONTRACTS
	We enter into foreign currency forward exchange contracts to cover the risk of exposure to exchange rate differences arising from inventory purchases on letters of credit. Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date.
	The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets:
	(In thousands)	Balance Sheet Component		September 30,				December 31,
				2013				2012
	Derivative financial instruments:
	Pharmsynthez Note Receivable and	Prepaid expenses and other current assets		$	6,755			$	—
	Purchase Option
	Neovasc common stock options/warrants	Investments, net		$	1,618			$	1,872
	Embedded conversion option	3.00% convertible senior notes, net of discount		$	99,823			$	—
		and estimated fair value of embedded
		derivatives
	Forward contracts (1)	Current portion of lines of credit and notes		$	3,899			$	1,294
		payable
	-1	The effect on loss in the forward contracts is recorded in Accrued expenses. The effect on income in the forward contracts is recorded in Prepaid expenses and other current assets.
	To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2013 and December 31, 2012, our derivative financial instruments do not meet the documentation requirements to be designated as hedges. Accordingly, we recognize the changes in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. The following table summarizes the (losses) and gains recorded during the three and nine months ended September 30, 2013 and 2012:
		Three months ended September 30,								Nine months ended September 30,
	(In thousands)	2013				2012				2013				2012
	Derivative gain (loss):
	Pharmsynthez Note Receivable and Purchase Option	$	(147	)		$	—			$	2,452			$	—
	Neovasc common stock options/warrants and BZNE Note	(545		)		201				700				1,368
	conversion feature
	Notes	(26,943		)		—				(41,818		)		—
	Forward contracts	(158		)		(32		)		(25		)		(59		)
	Total	$	(27,793	)		$	169			$	(38,691	)		$	1,309
	The outstanding forward contracts at September 30, 2013 and December 31, 2012, have been recorded at fair value, and their maturity details are as follows:
	(In thousands)		Contract value				Fair value at				Effect on income (loss)
	Days until maturity						September 30, 2013
	0 to 30		$	1,133			$	1,139			$	6
	31 to 60		1,058				1,039				(19		)
	61 to 90		945				939				(6		)
	91 to 120		272				271				(1		)
	121 to 180		516				511				(5		)
	More than 180		—				—				—
	Total		$	3,924			$	3,899			$	(25	)
	(In thousands)		Contract value				Fair value at				Effect on income (loss)
	Days until maturity						December 31, 2012
	0 to 30		$	—			$	—			$	—
	31 to 60		581				577				(4		)
	61 to 90		341				339				(2		)
	91 to 120		212				210				(2		)
	121 to 180		170				168				(2		)
	More than 180		—				—				—
	Total		$	1,304			$	1,294			$	(10	)

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	RELATED PARTY TRANSACTIONS
	On August 29, 2013, we acquired PROLOR pursuant to an Agreement and Plan of Merger dated as of April 23, 2013 in an all-stock transaction.  Until completion of the acquisition, Dr. Frost was PROLOR’s Chairman of the Board and a greater than 5% stockholder of PROLOR. Dr. Hsiao and Mr. Rubin were also directors and less than 5% stockholders of PROLOR.
	In January 2013, we entered into the Notes, with the Purchasers for the sale of $175.0 million aggregate principal amount of Notes in a private placement in reliance on exemptions from registration under the Securities Act. The Purchasers of the Notes include Frost Gamma Investments Trust, a trust affiliated with Dr. Frost, and Hsu Gamma Investment, L.P., an entity affiliated with Dr. Hsiao. The Notes were issued on January 30, 2013.
	In December 2012, we entered into a five-year lease agreement with AVI Properties, LLC (“AVI”), an entity affiliated with Dr. Jonathan Oppenheimer, OURLab’s Chief Executive Officer. The lease is for approximately 44,000 square feet of laboratory and office space in Nashville, Tennessee, where OURLab is based. The lease provides for payments of approximately $18 thousand per month in the first year, increasing annually if the consumer price index exceeds 5%, plus applicable sales tax. In addition to the rent, we pay a portion of operating expenses, property taxes and parking.
	During the nine months ended September 30, 2013, our FineTech subsidiary recorded revenue of $0.1 million for the sale of APIs to Teva Pharmaceutical Industries, Limited ("Teva"). Dr. Frost serves as the Chairman of the Board of Directors of Teva.
	In February 2012, we entered into a cooperative research funding and option agreement with The Scripps Research Institute (“TSRI”) to support research for the development of novel oligomeric compounds relating to our molecular diagnostics technology (the “Research Agreement”). Pursuant to the Research Agreement, we agreed to provide funding of approximately $0.9 million annually over a five year period. In conjunction with entering into the Research Agreement, we also entered into a license agreement with TSRI for technology relating to libraries of peptide tertiary amides. In addition, we entered into a second license with TSRI for technology relating to highly selective inhibitors of c-Jun-N-Terminal Kinases that may be useful for the treatment of various diseases, including Parkinson’s disease. We also entered into a research funding and option agreement to provide funding of approximately $0.2 million annually over three years to support further development of the technology. Dr. Frost served as a Trustee for TSRI until November 2012 and Dr. Richard Lerner, a member of our Board of Directors, served as its President until December 2011.
	In February 2012, we made a $1.0 million investment in ChromaDex. Other investors participating in the private financing included the Gamma Trust, Hsu Gamma, and Dr. Lerner. Following our investment, we own 1.5% of ChromaDex, the Gamma Trust owns approximately 16% of ChromaDex; Hsu Gamma owns approximately 1%; and certain of our directors own less 1%of ChromaDex.
	In February 2012, we purchased from BZNE $1.7 million of 10% secured convertible promissory notes (the “BZNE Notes”), convertible into BZNE common stock at a price equal to $0.20 per common share, which BZNE Notes are due and payable on February 24, 2014 and ten year warrants to purchase 8.5 million shares of BZNE common stock at an exercise price of $0.40 per share.
	Mr. Roberto Prego Novo is the Chairman of BZNE and presently serves as a consultant to us. Dr. Frost and Mr. Prego Novo previously invested in BZNE in February and March, 2011. On May 16, 2011, BZNE acquired the assets and assumed the liabilities of Aero Pharmaceuticals, Inc. (“Aero”) in exchange for which BZNE issued an aggregate of 8,331,396 shares of its restricted common stock to Aero. On September 21, 2011, BZNE issued an additional 13,914 shares to Aero due to the late filing of a registration statement. Prior to the transaction, Dr. Frost, through the Gamma Trust, beneficially owned approximately 46% of Aero’s issued and outstanding capital stock; Mr. Prego Novo owned approximately 23% of Aero’s issued and outstanding capital stock through Olyrca Trust; and Dr. Hsiao beneficially owned approximately 12% of Aero’s issued and outstanding stock. Each of Drs. Frost and Hsiao and Mr. Prego Novo beneficially owned approximately 9.2%, 1.7%, and 8.2% of BZNE, respectively, following the purchase of Aero by BZNE. Mr. Rubin beneficially owns less than 1% of BZNE as a result of his prior ownership of Aero shares. In April 2012 and June 2012, Dr. Frost, through the Gamma Trust, also made loans to BZNE in the principal amounts of $0.3 million and $0.1 million, respectively, which were initially secured by a first priority lien on a particular BZNE receivable. The notes to Gamma Trust were subsequently amended and Gamma Trust no longer holds a security interest in the BZNE receivables.
	In August 2011, we made an investment in Neovasc. Dr. Frost and other members of our management are shareholders of Neovasc. Prior to the investment, Dr. Frost beneficially owned approximately 36% of Neovasc, Dr. Hsiao owned approximately 6%, and Mr. Rubin owned less than 1%. Dr. Hsiao and Mr. Rubin also serve on the board of directors of Neovasc.
	In November 2010, we made an investment in Fabrus. In exchange for the investment, we acquired approximately 13% of Fabrus on a fully diluted basis. Our investment was part of a $2.1 million financing for Fabrus. Other investors participating in the financing include the Gamma Trust and Hsu Gamma. In connection with the financing, Drs. Frost and Hsiao joined the Fabrus Board of Managers. Dr. Lerner owns approximately 5% of Fabrus. Mr. Vaughn Smider, Founder and CEO of Fabrus, is an Assistant Professor at TSRI. Dr. Frost served as a Trustee for TSRI until November 2012, and Dr. Lerner served as President of TSRI until December 2011.
	In June 2010, we entered into a cooperative research and development agreement with Academia Sinica, Taipei, Taiwan (“Academia Sinica”), for pre-clinical work for a compound against various forms of cancer. Dr. Alice Yu, a member of our Board of Directors, is a Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica (“Genomics Research Center”). In connection with the Academia Sinica Agreement, we are required to pay Academia Sinica approximately $0.2 million over the term of the agreement.
	Effective in September 2009, we entered into an agreement pursuant to which we invested $2.5 million in Cocrystal in exchange for 1,701,723 shares of Cocrystal’s Convertible Series A Preferred Stock. A group of investors, led by the Frost Group LLC, which is a trust controlled by Dr. Frost, Dr. Hsaio and Mr. Rubin, (the “Cocrystal Investors”), previously invested $5.0 million in Cocrystal, and agreed to invest an additional $5.0 million payable in two equal installments in September 2009 and March 2010. As a result of an amendment to the Cocrystal Investors’ agreements dated June 9, 2009, we, rather than the Cocrystal Investors, made the first installment investment ($2.5 million) on September 21, 2009.
	In June 2009, we entered into a stock purchase agreement with Sorrento, pursuant to which we invested $2.3 million in Sorrento Therapeutics, Inc. ("Sorrento"). In exchange for the investment, we acquired approximately one-third of the outstanding common shares of Sorrento and received a fully-paid, exclusive license to the Sorrento antibody library for the discovery and development of therapeutic antibodies in the field of ophthalmology. On September 21, 2009, Sorrento entered into a merger transaction with Quikbyte Software, Inc. (“Quikbyte”). Prior to the merger transaction, certain investors, including Dr. Frost and other members of our management group, made an investment in Quikbyte. Dr. Lerner serves as a consultant and scientific advisory board member to Sorrento and owns less than 1% of its shares.
	In November 2007, we entered into an office lease with Frost Real Estate Holdings, LLC (“Frost Holdings”), an entity affiliated with Dr. Frost. The lease is for approximately 8,300 square feet of space in an office building in Miami, Florida, where our principal executive offices are located. The lease provides for payments of approximately $18 thousand per month in the first year increasing annually to $24 thousand per month in the fifth year, plus applicable sales tax. The rent is inclusive of operating expenses, property taxes and parking. The rent for the first year was reduced to reflect a $30 thousand credit for the costs of tenant improvements. In August 2012, we entered into a six-month extension on the same terms as the 2007 expiring lease and in February 2013, we agreed to extend the lease on a month-to-month basis.
	We reimburse Dr. Frost for Company-related use by Dr. Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr. Frost. We reimburse Dr. Frost in an amount equal to the cost of a first class airline ticket between the travel cities for each executive, including Dr. Frost, traveling on the airplane for Company-related business. We do not reimburse Dr. Frost for personal use of the airplane by Dr. Frost or any other executive; nor do we pay for any other fixed or variable operating costs of the airplane. For the three and nine months ended September 30, 2013, we reimbursed Dr. Frost approximately $19 thousand and $37 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives. For the three and nine months ended September 30, 2012, we reimbursed Dr. Frost approximately $52 thousand and $181 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	COMMITMENTS AND CONTINGENCIES
	In connection with our acquisitions of CURNA, OPKO Diagnostics, FineTech, Farmadiet, and Cytochroma, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result, as of September 30, 2013 , we recorded $69.2 million as contingent consideration, with $3.7 million recorded within Accrued expenses and $65.5 million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. Refer to Note 4.
	On April 29, 2013, we were named in a putative class action filed in the Eighth Judicial District Court in and for Clark County, Nevada against PROLOR, the members of the PROLOR Board of Directors, individually (including Drs. Frost and Hsiao and Steven Rubin), and the Company. From May 1, 2013 through May 6, 2013, we were named in an additional five putative class actions suits filed in the Eighth Judicial District Court in and for Clark County, Nevada against the same defendants. On July 17, 2013, these suits were consolidated, for all purposes, into an amended class action complaint, and on or around October 25, 2013, the plaintiffs filed a second amended consolidated class action complaint. The lawsuit is brought by purported holders of PROLOR's common stock, both individually and on behalf of a putative class of PROLOR's stockholders, asserting claims that PROLOR’s Board of Directors breached its fiduciary duties in connection with the merger by purportedly failing to maximize stockholder value, that PROLOR and its Board of Directors failed to disclose material information to PROLOR’s stockholders, and that the Company aided and abetted the alleged breaches of fiduciary duty. The lawsuit seeks monetary damages, including increased consideration to PROLOR’s stockholders, equitable relief, including, among other things, rescission of the Merger Agreement along with rescissionary damages, and an award of all costs, including reasonable attorneys’ fees. The Company denies the allegations and intends to vigorously defend the actions. It is too early to assess the probability of a favorable or unfavorable outcome or the loss or range of loss, if any.
	In November 2012, Adrian Goldstein, M.D., a former employee of OURLab, filed a complaint for declaratory judgment and alleged breach of contract against OURLab in the Chancery Court for Davidson County, Tennessee. Dr. Goldstein asserts in his complaint that OURLab breached his employment agreement and owes him additional compensation and further compensation for the value of OURLab under a “compensation for sale” provision set forth in his employment agreement. Dr. Goldstein seeks recovery of compensatory damages not to exceed $20 million, plus his attorney’s fees and litigation expenses. OURLab believes this action is without merit and is vigorously defending against plaintiff’s claims. It is too early to assess the probability of a favorable or unfavorable outcome or the loss or range of loss, if any.
	In October 2012, we received a letter from counsel to Optos, Inc., ("Optos") making certain indemnity claims against us in connection with the sale of our ophthalmic instrumentation business. In October 2013, we entered into a settlement agreement with Optos that resulted in payments to us and resolved all pending claims between the parties, including a termination of future royalty obligations from Optos to us.
	In July 2012, OURLab received a letter from AdvanceMed Corporation (“AdvanceMed”) regarding a post-payment review conducted by AdvanceMed (the “Post-Payment Review Letter”). The Post-Payment Review Letter originated with a post payment review audit by AdvanceMed of 183 claims submitted by OURLab to the Medicare program. OURLab believes that its billing practices were appropriate and it is following the appeal process set forth by Medicare. OURLab received a partially favorable determination, which reduced the amount of the alleged overpayment, and it continues to appeal the remaining alleged overpayments. No assurances can be given about the outcome of the appeal.
	We are a party to other litigation in the ordinary course of business. We do not believe that any such litigation will have a material adverse effect on our business, financial condition, or results of operations.
	We expect to incur substantial losses as we continue the development of our product candidates, continue our other research and development activities, and establish a sales and marketing infrastructure in anticipation of the commercialization of our diagnostic and pharmaceutical product candidates. We currently have limited commercialization capabilities, and it is possible that we may never successfully commercialize any of our diagnostic and pharmaceutical product candidates. We do not currently generate revenue from any of our diagnostic and pharmaceutical product candidates. Our research and development activities are budgeted to expand over a period of time and will require further resources if we are to be successful. As a result, we believe that our operating losses are likely to be substantial over the next several years. We may need to obtain additional funds to further develop our research and development programs, and there can be no assurance that additional capital will be available to us on acceptable terms, or at all.

Segments

Segments	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
SEGMENTS	'
	SEGMENTS
	We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain and Brazil. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OURLab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
	Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
		For the three months ended September 30,						For the nine months ended September 30,
	(In thousands)	2013			2012			2013			2012
	Product revenues:
	Pharmaceuticals	$	16,563		$	11,495		$	50,708		$	30,051
	Diagnostics	—			—			—			—
	Corporate	—			—			—			—
		$	16,563		$	11,495		$	50,708		$	30,051
	Revenue from services:
	Pharmaceuticals	$	—		$	—		$	—		$	—
	Diagnostics	2,710			43			8,870			173
	Corporate	60			57			180			159
		$	2,770		$	100		$	9,050		$	332
	Revenue from transfer of intellectual property:
	Pharmaceuticals	$	913		$	—		$	14,720		$	—
	Diagnostics	395			200			1,360			400
	Corporate	—			—			—			—
		$	1,308		$	200		$	16,080		$	400
	Operating (loss) income:
	Pharmaceuticals	$	(11,126	)	$	(1,755	)	$	(7,171	)	$	(5,072	)
	Diagnostics	(399		)	(3,810		)	(16,783		)	(12,835		)
	Corporate	(6,606		)	(3,804		)	(17,393		)	(9,650		)
	Less: Operating loss attributable to noncontrolling interests	(879		)	—			(2,419		)	—
		$	(19,010	)	$	(9,369	)	$	(43,766	)	$	(27,557	)
	Depreciation and amortization:
	Pharmaceuticals	$	2,020		$	1,780		$	5,417		$	4,805
	Diagnostics	1,717			841			5,110			2,510
	Corporate	31			44			121			132
		$	3,768		$	2,665		$	10,648		$	7,447
	Revenues:
	United States	$	4,078		$	300		$	25,130		$	732
	Chile	7,993			6,781			24,216			19,669
	Spain	4,026			1,997			13,503			1,997
	Israel	3,099			1,516			9,666			4,661
	Mexico	1,445			1,201			3,323			3,724
		$	20,641		$	11,795		$	75,838		$	30,783
	(In thousands)	September 30,			December 31,
		2013			2012
	Assets:
	Pharmaceuticals	$	1,087,950		$	142,299
	Diagnostics	114,434			112,422
	Corporate	180,598			35,109
		$	1,382,982		$	289,830
	Goodwill:
	Pharmaceuticals	$	174,734		$	32,844
	Diagnostics	47,606			47,606
	Corporate	—			—
		$	222,340		$	80,450
	During the three and nine months ended September 30, 2013 and 2012, no customer represented more than 10% of our total revenue. As of September 30, 2013 and December 31, 2012, no customer represented more than 10% of our accounts receivable balance.

Series_D_Preferred_Stock_Redem

Series D Preferred Stock Redemption	9 Months Ended
	Sep. 30, 2013
Temporary Equity [Abstract]	'
SERIES D PREFERRED STOCK REDEMPTION	'
	SERIES D PREFERRED STOCK REDEMPTION
	On March 1, 2013, our Board of Directors declared a cash dividend to all Series D Preferred Stockholders as of March 8, 2013. The total cash dividend paid was approximately $3.0 million. In addition, we also exercised our option to convert all 1,129,032 shares of our outstanding Series D Preferred Stock into 11,290,320 shares of our Common Stock effective as of March 8, 2013. Following the conversion there are no outstanding shares of Series D Preferred Stock.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	SUBSEQUENT EVENTS
	We have reviewed all subsequent events and transactions that occurred after the date of our September 30, 2013 condensed consolidated balance sheet date, through the time of filing this Quarterly Report on Form 10-Q.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of presentation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary to present fairly the Company’s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the three and nine months ended September 30, 2013, are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2013 or for future periods. The unaudited condensed consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012.
Reclassifications	'
	Reclassifications and correction of an error. Certain prior year amounts in the condensed consolidated financial statements have been reclassified to conform with the 2013 presentation. Due to the acquisition of OPKO OURLab, LLC (formerly Prost-Data, Inc.), our CLIA certified laboratory business (“OURLab”) in December 2012, we changed our segment presentation to include diagnostics as a reportable segment. As a result of this change in reportable segments, we restated certain prior year amounts in the condensed consolidated financial statements to conform with the 2013 presentation. These reclassifications had no impact on our results of operations.
Principles of consolidation	'
	Principles of consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of OPKO Health, Inc., our wholly-owned subsidiaries and variable interest entities (“VIEs”) in which we are deemed to be the primary beneficiary. All significant intercompany accounts and transactions are eliminated in consolidation.
Use of estimates	'
	Use of estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents	'
	Cash and cash equivalents. Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.
Inventories	'
	Inventories. Inventories are valued at the lower of cost or market (net realizable value). Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost or market.
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired when accounted for by the purchase method of accounting and arose from our acquisitions. Goodwill and other intangible assets acquired in business combinations, licensing and other transactions at September 30, 2013 and December 31, 2012 were $1.1 billion and $0.2 billion, respectively.
	Assets acquired and liabilities assumed in business combinations, licensing and other transactions are recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. We determined the fair value of intangible assets, including in-process research and development (“IPR&D”), using the “income method.”
	Goodwill is tested at least annually for impairment, or when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, on an enterprise level by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that its fair value exceeds the carrying value.
Fair value measurements	'
	Fair value measurements. The carrying amounts of our cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term maturities of these instruments. Investments that are considered available for sale as of September 30, 2013 are carried at fair value.
	Short-term investments, which we invest in from time to time, include bank deposits, corporate notes, U.S. treasury securities and U.S. government agency securities with original maturities of greater than 90 days and remaining maturities of less than one year. Long-term investments include corporate notes, U.S. treasury securities and U.S. government agency securities with maturities greater than one year.
	In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.
Contingent consideration	'
	Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as contingent consideration income. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.
Derivative financial instruments	'
	Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations, when they occur, the only exception being derivatives that qualify as hedges. For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2013 and December 31, 2012, our forward contracts for inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognize all changes in the fair values of our derivatives instruments in Fair value changes of derivatives instruments, net, in our Condensed Consolidated Statement of Operations.
Revenue recognition	'
	Revenue recognition. Generally, we recognize revenue from product sales when goods are shipped and title and risk of loss transfer to our customers. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and management’s evaluation of specific factors that may increase or decrease the risk of product returns.
	Revenue for laboratory services are recognized on the accrual basis at the time test results are reported, which approximates when services are provided. Services are provided to certain patients covered by various third-party payer programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services under third-party payer programs are included in sales net of allowances for contractual discounts and allowances for differences between the amounts billed and estimated program payment amounts. Adjustments to the estimated payment amounts based on final settlement with the programs are recorded upon settlement as an adjustment to revenue. For the three and nine months ended September 30, 2013, revenue from services also includes $0.2 million and $0.6 million, respectively, of revenue related to our consulting agreement with Neovasc, Inc. (“Neovasc”) and to revenue related to molecular diagnostics collaboration agreements. For the three and nine months ended September 30, 2012, revenue from services included $0.1 million and $0.3 million, respectively, of revenue related to our consulting agreement with Neovasc and to revenue related to molecular diagnostics collaboration agreements. We recognize this revenue on a straight-line basis over the contractual term of the agreements.
	Revenue from transfer of intellectual property includes revenue related to the sale, license or transfer of intellectual property such as upfront license payments, license fees and milestone payments received through our license, collaboration and commercialization agreements. We analyze our multiple-element arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting.
	Non-refundable license fees for the out-license of our technology are recognized depending on the provisions of each agreement. We recognize non-refundable upfront license payments as revenue upon receipt if the license has standalone value and the fair value of our undelivered obligations, if any, can be determined. If the license is considered to have standalone value but the fair value of any of the undelivered items cannot be determined, the license payments are recognized as revenue over the period of our performance for such undelivered items or services. License fees with ongoing involvement or performance obligations are recorded as deferred revenue, included in Accrued expenses or Other long-term liabilities, when received and generally are recognized ratably over the period of such performance obligation only after both the license period has commenced and we have delivered the technology.
	The assessment of our obligations and related performance periods requires significant management judgment. If an agreement contains research and development obligations, the relevant time period for the research and development phase is based on management estimates and could vary depending on the outcome of clinical trials and the regulatory approval process. Such changes could materially impact the revenue recognized, and as a result, management reviews the estimates related to the relevant time period of research and development on a quarterly basis. For the nine months ended September 30, 2013, we recorded $16.1 million of revenue from the transfer of intellectual property, of which $12.5 million related to the sale of substantially all of our assets in the field of RNA interference to RXi Pharmaceuticals Corporation (“RXi”) and $3.2 million related to the rights granted to OAO Pharmsynthez ("Pharmsynthez") of certain technologies. Refer to Note 5.
	Revenue from milestone payments related to arrangements under which we have continuing performance obligations are recognized as Revenue from transfer of intellectual property upon achievement of the milestone only if all of the following conditions are met: the milestone payments are non-refundable; there was substantive uncertainty at the date of entering into the arrangement that the milestone would be achieved; the milestone is commensurate with either the vendor’s performance to achieve the milestone or the enhancement of the value of the delivered item by the vendor; the milestone relates solely to past performance; and the amount of the milestone is reasonable in relation to the effort expended or the risk associated with the achievement of the milestone. If any of these conditions are not met, the milestone payments are not considered to be substantive and are, therefore, deferred and recognized as Revenue from transfer of intellectual property over the term of the arrangement as we complete our performance obligations.
Allowance for doubtful accounts	'
	Allowance for doubtful accounts. We analyze accounts receivable and historical bad debt levels, customer credit worthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts using the specific identification method. Our reported net loss is directly affected by our estimate of the collectability of accounts receivable.
Equity-based compensation	'
	Equity-based compensation. We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the statement of operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits, realized from the exercise of stock options as a financing cash inflow rather than as a reduction of taxes paid in cash flow from operations. Equity-based compensation arrangements to non-employees are recorded at their fair value on the measurement date. The measurement of equity-based compensation is subject to periodic adjustment as the underlying equity instruments vest.
Research and development expenses	'
	Research and development expenses. Research and development expenses include external and internal expenses, partially offset by third-party grants and fundings arising from collaboration agreements. External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and stock-based compensation expense. Other unallocated internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.
Segment reporting	'
	Segment reporting. Our chief operating decision-maker (“CODM”) is comprised of our executive management with the oversight of our Board of Directors. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain and Brazil. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OURLab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Variable interest entities	'
	Variable interest entities. The consolidation of VIEs is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.
Investments	'
	Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or investments available for sale based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations. Refer to Note 5. For investments classified as available for sale, we record changes in their fair value as unrealized gain or loss in Other comprehensive loss based on their closing price per share at the end of each reporting period.

Composition_of_Certain_Financi1

Composition of Certain Financial Statement Captions (Tables)	9 Months Ended
	Sep. 30, 2013
Compositions of Certain Financial Statement Captions [Abstract]	'
Composition of certain financial statement captions	'
	(In thousands)	September 30,			December 31,
		2013			2012
	Accounts receivable, net:
	Accounts receivable	$	22,506		$	21,636
	Less: allowance for doubtful accounts	(1,134		)	(474		)
		$	21,372		$	21,162
	Inventories, net:
	Finished products	$	14,775		$	17,963
	Work in-process	1,450			688
	Raw materials	4,426			4,923
	Less: inventory reserve	(1,135		)	(1,313		)
		$	19,516		$	22,261
	Prepaid expenses and other current assets:
	Prepaid supplies	$	839		$	443
	Prepaid insurance	843			301
	Pharmsynthez Note Receivable and Purchase Option	6,755			—
	Other receivables	3,818			886
	Taxes recoverable	2,992			1,493
	Other	4,304			4,750
		$	19,551		$	7,873
	Intangible assets, net:
	Technologies	$	52,947		$	52,810
	Customer relationships	22,883			23,088
	Product registrations	9,861			9,637
	Tradenames	3,702			3,746
	Covenants not to compete	8,667			8,662
	Other	1,177			367
	Less:  accumulated amortization	(21,904		)	(14,072		)
		$	77,333		$	84,238
	Accrued expenses:
	Taxes payable	$	3,225		$	1,614
	Deferred revenue	7,040			1,518
	Clinical trials	3,543			50
	Professional fees	7,203			675
	Employee benefits	6,416			3,319
	Deferred acquisition payments, net of discount	5,335			6,172
	Contingent consideration	3,695			5,126
	Interest payable related to the Notes	925			—
	Other	5,887			6,182
		$	43,269		$	24,656
	(In thousands)	September 30,			December 31,
		2013			2012
	Other long-term liabilities:
	Contingent consideration – Cytochroma	$	51,447		$	—
	Contingent consideration – Farmadiet	542			532
	Contingent consideration – OPKO Diagnostics	12,976			11,310
	Contingent consideration – FineTech	—			2,578
	Contingent consideration – CURNA	549			510
	Deferred acquisition payments, net of discount	—			3,931
	Mortgages and other debts payable	3,350			5,150
	Deferred tax liabilities	164,892			9,777
	Other, including deferred revenue	1,006			380
		$	234,762		$	34,168

Acquisitions_Investments_and_L1

Acquisitions, Investments, and Licenses (Tables)	9 Months Ended
	Sep. 30, 2013
Business Acquisition [Line Items]	'
Estimated fair value of the net assets acquired and liabilities assumed in the acquisition of at the date of acquisition	'
	The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the acquisitions of Cytochroma and PROLOR at the dates of acquisition, which are subject to change while contingencies that existed on the acquisition date are resolved:
	(In thousands)	Cytochroma				PROLOR
	Current assets (1)	$	1,224			$	21,500
	Intangible assets:
	In-process research and development	191,530				590,200
	Patents	210				—
	Total intangible assets	191,740				590,200
	Goodwill	2,411				139,784
	Property, plant and equipment	306				1,057
	Other assets	—				371
	Accounts payable and accrued expenses	(1,069		)		(9,866		)
	Deferred tax liability	—				(156,403		)
	Total purchase price	$	194,612			$	586,643
	(1)Current assets include cash of $0.4 million and $20.5 million related to the Cytochroma and PROLOR acquisitions, respectively.
Pro forma disclosure for acquisitions	'
	The following table includes the pro forma results for the three and nine months ended September 30, 2013 and 2012 of the combined companies as though the acquisition of Cytochroma and PROLOR had been completed as of the beginning of each period, respectively.
		For the three months ended September 30,							For the nine months ended September 30,
	(In thousands)	2013				2012			2013			2012
	Revenues	$	20,641			$	13,976		$	75,838		$	37,327
	Net loss	$	(75,858	)		$	(15,745	)	$	130,118		$	(43,864	)
	Net loss attributable to common shareholders	$	(75,055	)		$	(16,302	)	$	(128,229	)	$	(45,534	)
	Basic and diluted loss per share	$	(0.19	)		$	(0.04	)	$	(0.32	)	$	(0.12	)
Maximum exposure of unconsolidated investments	'
	The following table reflects our maximum exposure, accounting method, ownership interest and underlying equity in net assets of each of our unconsolidated investments as of September 30, 2013:
	(Dollars in thousands, except per share prices)		Year		Accounting method		Ownership at		Investment			Underlying equity in net assets			Closing share price
	Investee name		invested				September 30,								at September 30, 2013
							2013								for investments
															available for sale
	Sorrento		2009		Equity method		14	%	$	2,300		$	821
	Cocrystal		2009		Equity method		16	%	2,500			358
	Neovasc		2011		Equity method		6	%	3,798			454
	Fabrus		2010		VIE, equity method		13	%	650			(108		)
	BZNE common stock		2012		VIE, equity method		11	%	1,276			(1,184		)
	RXi		2013		Equity method		19	%	15,000			2,847
	Pharmsynthez		2013		Equity method		11	%	5,036			5,156
	TESARO		2010		Investment available for sale		1	%	56							$	38.74
	Neovasc options		2011		Investment available for sale		N/A		925						CA	$	2.35
	BZNE Note and conversion feature		2012		VIE, investment available for sale		N/A		1,700
	ChromaDex		2012		Investment available for sale		1	%	1,320							$	0.81
	Plus unrealized/realized gains on investments, options and warrants, net								2,708
	Less accumulated losses in investees								(12,579		)
	Total carrying value of equity method investees and investments, available for sale								$	24,690
SciVac [Member]	'
Business Acquisition [Line Items]	'
Summary of consolidated assets and non-recourse liabilities related to SciVac	'
	The following table represents the consolidated assets and non-recourse liabilities related to SciVac as of September 30, 2013 and December 31, 2012. These assets are owned by, and these liabilities are obligations of, SciVac, not us.
	(In thousands)	September 30,				December 31,
		2013				2012
	Assets
	Current assets:
	Cash and cash equivalents	$	136			$	174
	Accounts receivable, net	205				387
	Inventories, net	1,653				1,092
	Prepaid expenses and other current assets	185				199
	Total current assets	2,179				1,852
	Property, plant and equipment, net	1,410				1,539
	Intangible assets, net	1,122				1,154
	Goodwill	841				796
	Other assets	312				231
	Total assets	$	5,864			$	5,572
	Liabilities
	Current liabilities:
	Accounts payable	$	1,129			$	1,108
	Accrued expenses	5,969				2,859
	Notes payable	1,284				—
	Total current liabilities	8,382				3,967
	Other long-term liabilities	279				1,529
	Total liabilities	$	8,661			$	5,496

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Instrument [Line Items]	'
Schedule of principal amounts, unamortized discount and net carrying amounts	'
	The following table sets forth information related to the 3.00% convertible senior notes which is included our Condensed Consolidated Balance Sheets:
	(In thousands)	Embedded conversion option			Convertible Notes			Discount			Total
	Balance at December 31, 2012	$	—		$	—		$	—		$	—
	Issuance of 3.00% convertible notes	59,204			175,000			(59,204		)	175,000
	Amortization of debt discount	—			—			4,866			4,866
	Debt discount write-off associated with conversion	—			—			5,368			5,368
	of debt
	Change in fair value of embedded derivative	41,818			—			—			41,818
	Conversion	(1,199		)	(16,936		)	—			(18,135		)
	Balance at September 30, 2013	$	99,823		$	158,064		$	(48,970	)	$	208,917
Summary of lines of credit	'
	The following table summarizes the amounts outstanding under the lines of credit:
	(Dollars in thousands)							Balance Outstanding
	Lender		Interest rate on		Credit line			September 30,			December 31,
			borrowings		capacity			2013			2012
	Itau Bank		8.04	%	$	3,000		$	2,207		$	2,738
	Bank of Chile		7.8	%	3,000			1,967			2,292
	BICE Bank		5.5	%	1,500			867			2,451
	Corp Banca		5.5	%	—			28			1,248
	BBVA Bank		8.29	%	2,500			1,230			2,823
	Penta Bank		9.48	%	800			992			833
	Security Bank		7.56	%	1,500			1,063			—
	BCI		5.5	%	1,000			1,216			—
	Estado Bank		6.88	%	2,000			1,732			1,963
	Sabadell Bank		7.6	%	203			—			3
	Bilbao Vizcaya Bank		4.9	%	406			91			377
	Banco Popular		8.25	%	406			—			260
	Santander Bank		6	%	203			—			—
	Banesto		5.8	%	203			4			163
	Banca March		6.25	%	270			—			44
	Total				$	16,991		$	11,397		$	15,195
Farmadiet Acquisition [Member]	'
Debt Instrument [Line Items]	'
Schedule of principal amounts, unamortized discount and net carrying amounts	'
	At September 30, 2013 and December 31, 2012, we had mortgage notes and other debt payables related to Farmadiet as follows:
	(In thousands)	September 30,			December 31,
		2013			2012
	Current portion of lines of credit and notes payable	$	1,796		$	2,331
	Other long-term liabilities	3,350			3,916
	Total mortgage notes and other debt payables	$	5,146		$	6,247
Notes [Member]	'
Debt Instrument [Line Items]	'
Inputs to lattice model used to value the embedded derivative	'
	The following table sets forth the inputs to the lattice model used to value the embedded derivative:
		September 30, 2013			Issuance Date
	Stock price	$	8.81		$	6.2
	Conversion Rate	141.4827			141.4827
	Conversion Price	$	7.07		$	7.07
	Maturity date	February 1, 2033			February 1, 2033
	Risk-free interest rate	1.5		%	1.12		%
	Estimated stock volatility	40		%	40		%
	Estimated credit spread	948 basis points			944 basis points
Fair value of notes with and without the embedded derivatives and fair value of embedded derivatives	'
	The following table sets forth the fair value of the Notes with and without the embedded derivatives, and the fair value of the embedded derivatives as of the issuance date and September 30, 2013. At September 30, 2013 and at issuance date the principal amount of the Notes was $158.1 million and $175.0 million, respectively:
	(In thousands)	September 30, 2013			Issuance Date
	Fair value of Notes:
	With the embedded derivatives	$	210,105		$	175,000
	Without the embedded derivatives	$	110,282		$	115,796
	Estimated fair value of the embedded derivatives	$	99,823		$	59,204

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Changes in accumulated other comprehensive income net of tax	'
	For the nine months ended September 30, 2013, changes in Accumulated other comprehensive income, net of tax, were as follows:
	(In thousands)	Foreign			Unrealized
		currency			gains in
					Accumulated
					OCI
	Balance at December 31, 2012	$	3,196		$	4,160
	Other comprehensive income before reclassifications, net of tax (1)	(1,395		)	1,869
	Amounts reclassified from accumulated other comprehensive income, net of tax (1)	—			(4,593		)
	Net other comprehensive income	(1,395		)	(2,724		)
	Balance at September 30, 2013	$	1,801		$	1,436
	-1	Effective tax rate of 38.47%.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Summary of investments classified as available for sale, and carried at fair value	'
	A summary of our investments as of September 30, 2013, classified as available for sale, and carried at fair value is as follows:
		As of September 30, 2013
	(In thousands)	Amortized			Gross			Gross			Gain/(Loss)			Fair
		Cost			unrealized			unrealized			in			value
					gains in			losses in			Accumulated
					Accumulated			Accumulated			Deficit
					OCI			OCI
	Common stock investments, available for sale	$	1,376		$	1,417		$	—		$	—		$	2,793
	BZNE Note and conversion feature	1,700			53			—			287			2,040
	Neovasc common stock options	925			714			(202		)	181			1,618
	U.S. Treasury securities	25,004			—			—			—			25,004
	Total assets	$	29,005		$	2,184		$	(202	)	$	468		$	31,455
	A summary of our investments as of December 31, 2012, classified as available for sale, and carried at fair value is as follows:
		As of December 31, 2012
	(In thousands)	Amortized			Gross			Gross			Gain/(Loss)			Fair
		Cost			unrealized			unrealized			in			value
					gains in			losses in			Accumulated
					Accumulated			Accumulated			Deficit
					OCI			OCI
	Common stock investments, available for sale	$	2,051		$	6,185		$	—		$	—		$	8,236
	BZNE Note and conversion feature	1,700			53			—			287			2,040
	Neovasc common stock options	925			293			—			176			1,394
	Neovasc common stock warrants	659			194			—			(375		)	478
	Total assets	$	5,335		$	6,725		$	—		$	88		$	12,148
Financial assets and liabilities measured at fair value on a recurring basis	'
	Our financial assets and liabilities measured at fair value on a recurring basis are as follows:
		Fair value measurements as of September 30, 2013
	(In thousands)	Quoted			Significant			Significant			Total
		prices in			other			unobservable
		active			observable			inputs
		markets for			inputs			(Level 3)
		identical			(Level 2)
		assets
		(Level 1)
	Assets:
	Money market funds	$	116,477		$	—		$	—		$	116,477
	U.S. Treasury securities	—			25,004			—			25,004
	Certificates of deposit	—			827			—			827
	Pharmsynthez Note Receivable and Purchase Option	—			6,755			—			6,755
	Common stock investments, available for sale	2,793			—			—			2,793
	BZNE Note and conversation feature	—			—			2,040			2,040
	Neovasc common stock options	—			1,618			—			1,618
	Total assets	$	119,270		$	34,204		$	2,040		$	155,514
	Liabilities:
	Forward contracts	$	—		$	(25	)	$	—		$	(25	)
	Embedded conversion option	—			—			99,823			99,823
	Deferred acquisition payments, net of discount	—			—			5,335			5,335
	Contingent consideration:
	CURNA	—			—			549			549
	OPKO Diagnostics	—			—			12,976			12,976
	FineTech	—			—			2,862			2,862
	Cytochroma	—			—			51,447			51,447
	Farmadiet	—			—			1,375			1,375
	Total liabilities	$	—		$	(25	)	$	174,367		$	174,342
		Fair value measurements as of December 31, 2012
	(In thousands)	Quoted			Significant			Significant			Total
		prices in			other			unobservable
		active			observable			inputs
		markets for			inputs			(Level 3)
		identical			(Level 2)
		assets
		(Level 1)
	Assets:
	Money market funds	$	18,716		$	—		$	—		$	18,716
	Certificates of deposit	—			820			—			820
	Common stock investments, available for sale	8,236			—			—			8,236
	BZNE Note and conversation feature	—			—			2,040			2,040
	Neovasc common stock options	—			1,394			—			1,394
	Neovasc common stock warrants	—			478			—			478
	Total assets	$	26,952		$	2,692		$	2,040		$	31,684
	Liabilities:
	Forward contracts	$	—		$	10		$	—		$	10
	Deferred acquisition payments, net of discount	—			—			10,103			10,103
	Contingent consideration:
	CURNA	—			—			510			510
	OPKO Diagnostics	—			—			12,974			12,974
	FineTech	—			—			5,262			5,262
	Farmadiet	—			—			1,310			1,310
	Total liabilities	$	—		$	10		$	30,159		$	30,169
The carrying amount and estimated fair value of our long-term debt	'
	. The fair value of the Notes is determined using a binomial lattice approach in order to estimate the fair value of the embedded derivative in the Notes. Refer to Note 6.
		September 30, 2013
	(In thousands)	Carrying			Total			Level 1			Level 2			Level 3
		Value			Fair Value
	Notes	$	109,094		$	110,282		$	—		$	—		$	110,282
Reconcile the beginning and ending balances of Level 3 assets and liabilities	'
	The following tables reconcile the beginning and ending balances of our Level 3 assets and liabilities as of September 30, 2013 and December 31, 2012:
		September 30, 2013
	(In thousands)	BZNE Note			Contingent			Deferred			Embedded
		and			consideration			acquisition			conversion
		conversion						payments, net			option
		feature						of discount
	Balance at December 31, 2012	$	2,040		$	20,056		$	10,103		$	—
	Additions	—			47,710			—			59,204
	Total losses (gains) for the period:
	Included in results of operations	—			4,204			597			41,818
	Conversion of the Notes	—			—			—			(1,199		)
	Payments	—			(2,761		)	(5,365		)	—
	Balance at September 30, 2013	$	2,040		$	69,209		$	5,335		$	99,823
		December 31, 2012
	(In thousands)	BZNE Note			Contingent			Deferred
		and			consideration			acquisition
		conversion						payments, net
		feature						of discount
	Balance at December 31, 2011	$	—		$	18,002		$	—
	Additions	1,700			1,234			9,673
	Total losses (gains) for the period:
	Included in results of operations	1,563			820			430
	Included in Other comprehensive loss	53			—			—
	Transfer out to equity method investment	(1,276		)	—			—
	Balance at December 31, 2012	$	2,040		$	20,056		$	10,103

Derivative_Contracts_Tables

Derivative Contracts (Tables)	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Summary of fair values and derivative financial instrument	'
	The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets:
	(In thousands)	Balance Sheet Component		September 30,				December 31,
				2013				2012
	Derivative financial instruments:
	Pharmsynthez Note Receivable and	Prepaid expenses and other current assets		$	6,755			$	—
	Purchase Option
	Neovasc common stock options/warrants	Investments, net		$	1,618			$	1,872
	Embedded conversion option	3.00% convertible senior notes, net of discount		$	99,823			$	—
		and estimated fair value of embedded
		derivatives
	Forward contracts (1)	Current portion of lines of credit and notes		$	3,899			$	1,294
		payable
	-1	The effect on loss in the forward contracts is recorded in Accrued expenses. The effect on income in the forward contracts is recorded in Prepaid expenses and other current assets.
Summary of loss (gain) recorded in Fair value changes of derivative financial instruments	'
	The following table summarizes the (losses) and gains recorded during the three and nine months ended September 30, 2013 and 2012:
		Three months ended September 30,								Nine months ended September 30,
	(In thousands)	2013				2012				2013				2012
	Derivative gain (loss):
	Pharmsynthez Note Receivable and Purchase Option	$	(147	)		$	—			$	2,452			$	—
	Neovasc common stock options/warrants and BZNE Note	(545		)		201				700				1,368
	conversion feature
	Notes	(26,943		)		—				(41,818		)		—
	Forward contracts	(158		)		(32		)		(25		)		(59		)
	Total	$	(27,793	)		$	169			$	(38,691	)		$	1,309
Outstanding contracts recorded at fair value and their maturity details	'
	The outstanding forward contracts at September 30, 2013 and December 31, 2012, have been recorded at fair value, and their maturity details are as follows:
	(In thousands)		Contract value				Fair value at				Effect on income (loss)
	Days until maturity						September 30, 2013
	0 to 30		$	1,133			$	1,139			$	6
	31 to 60		1,058				1,039				(19		)
	61 to 90		945				939				(6		)
	91 to 120		272				271				(1		)
	121 to 180		516				511				(5		)
	More than 180		—				—				—
	Total		$	3,924			$	3,899			$	(25	)
	(In thousands)		Contract value				Fair value at				Effect on income (loss)
	Days until maturity						December 31, 2012
	0 to 30		$	—			$	—			$	—
	31 to 60		581				577				(4		)
	61 to 90		341				339				(2		)
	91 to 120		212				210				(2		)
	121 to 180		170				168				(2		)
	More than 180		—				—				—
	Total		$	1,304			$	1,294			$	(10	)

Segments_Tables

Segments (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Information regarding our geographic activities	'
	Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
		For the three months ended September 30,						For the nine months ended September 30,
	(In thousands)	2013			2012			2013			2012
	Product revenues:
	Pharmaceuticals	$	16,563		$	11,495		$	50,708		$	30,051
	Diagnostics	—			—			—			—
	Corporate	—			—			—			—
		$	16,563		$	11,495		$	50,708		$	30,051
	Revenue from services:
	Pharmaceuticals	$	—		$	—		$	—		$	—
	Diagnostics	2,710			43			8,870			173
	Corporate	60			57			180			159
		$	2,770		$	100		$	9,050		$	332
	Revenue from transfer of intellectual property:
	Pharmaceuticals	$	913		$	—		$	14,720		$	—
	Diagnostics	395			200			1,360			400
	Corporate	—			—			—			—
		$	1,308		$	200		$	16,080		$	400
	Operating (loss) income:
	Pharmaceuticals	$	(11,126	)	$	(1,755	)	$	(7,171	)	$	(5,072	)
	Diagnostics	(399		)	(3,810		)	(16,783		)	(12,835		)
	Corporate	(6,606		)	(3,804		)	(17,393		)	(9,650		)
	Less: Operating loss attributable to noncontrolling interests	(879		)	—			(2,419		)	—
		$	(19,010	)	$	(9,369	)	$	(43,766	)	$	(27,557	)
	Depreciation and amortization:
	Pharmaceuticals	$	2,020		$	1,780		$	5,417		$	4,805
	Diagnostics	1,717			841			5,110			2,510
	Corporate	31			44			121			132
		$	3,768		$	2,665		$	10,648		$	7,447
	Revenues:
	United States	$	4,078		$	300		$	25,130		$	732
	Chile	7,993			6,781			24,216			19,669
	Spain	4,026			1,997			13,503			1,997
	Israel	3,099			1,516			9,666			4,661
	Mexico	1,445			1,201			3,323			3,724
		$	20,641		$	11,795		$	75,838		$	30,783
	(In thousands)	September 30,			December 31,
		2013			2012
	Assets:
	Pharmaceuticals	$	1,087,950		$	142,299
	Diagnostics	114,434			112,422
	Corporate	180,598			35,109
		$	1,382,982		$	289,830
	Goodwill:
	Pharmaceuticals	$	174,734		$	32,844
	Diagnostics	47,606			47,606
	Corporate	—			—
		$	222,340		$	80,450

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Apr. 30, 2013

Sep. 30, 2013

Segment

Neovasc [Member]

Neovasc [Member]

Neovasc [Member]

Neovasc [Member]

Pharmaceutical [Member]

Diagnostics [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Pharmsynthez [Member]

Pharmsynthez [Member]

Pharmsynthez [Member]

Rxi Pharmaceuticals Corporation [Member]

Segment

Segment

Summary of Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction of research and development expense from equity based compensation expense

'

'

'

'

'

'

'

'

'

'

'

$2,700,000

$2,700,000

'

'

'

'

Reduction of research and development expense from equity based compensation expense (usd per share)

'

'

'

'

'

'

'

'

'

'

'

$0.01

$0.01

'

'

'

'

Goodwill and intangible assets

1,100,000,000

'

1,100,000,000

'

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from services

2,770,000

100,000

9,050,000

332,000

'

200,000

100,000

600,000

300,000

'

'

'

'

'

'

'

'

Revenue from transfer of intellectual property

1,308,000

200,000

16,080,000

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue related to sale of intellectual property

'

'

12,500,000

0

'

'

'

'

'

'

'

'

'

'

'

'

12,500,000

Revenue related to our license agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

1,300,000

3,200,000

'

'

Total deferred revenue related to other revenues

7,900,000

'

7,900,000

'

1,900,000

'

'

'

'

'

'

'

'

'

'

9,500,000

'

Allowance for doubtful accounts receivable

1,134,000

'

1,134,000

'

474,000

'

'

'

'

'

'

'

'

'

'

'

'

Equity-based compensation expense for continuing operations

$400,000

$1,100,000

$7,411,000

$3,281,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of reportable segments

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of operating segments

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

Loss_Per_Share_Details

Loss Per Share (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of common stock warrant and common stock options exercised	3,206,230	161,264	4,933,976	750,162
Number of common stock issued for stock warrant and stock options exercised	'	160,411	4,818,462	748,783
Shares surrendered in lieu of cash payment	'	853	115,514	1,379
Common Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Potential common shares	35,157,966	26,022,072	31,659,650	26,836,546

Composition_of_Certain_Financi2

Composition of Certain Financial Statement Captions (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts receivable, net:	'		'
Accounts receivable	$22,506		$21,636
Less: allowance for doubtful accounts	-1,134		-474
Accounts receivable, net	21,372	[1]	21,162	[1]
Inventories, net:	'		'
Finished products	14,775		17,963
Work in-process	1,450		688
Raw materials	4,426		4,923
Less: inventory reserve	-1,135		-1,313
Inventory, net	19,516	[1]	22,261	[1]
Prepaid expense and other assets:	'		'
Prepaid supplies	839		443
Prepaid insurance	843		301
Pharmsynthez Note Receivable and Purchase Option	6,755		0
Other receivables	3,818		886
Taxes recoverable	2,992		1,493
Other	4,304		4,750
Prepaid expenses and other current assets	19,551	[1]	7,873	[1]
Intangible assets, net:	'		'
Less: accumulated amortization	21,904		14,072
Intangible assets, net	77,333	[1]	84,238	[1]
Accrued expenses:	'		'
Taxes payable	3,225		1,614
Deferred revenue	7,040		1,518
Clinical trials	3,543		50
Professional fees	7,203		675
Employee benefits	6,416		3,319
Deferred acquisition payments, net of discount	5,335		6,172
Contingent consideration	3,695		5,126
Interest payable related to the Notes	925		0
Other	5,887		6,182
Accrued expenses	43,269	[1]	24,656	[1]
Other long-term liabilities:	'		'
Deferred acquisition payments, net of discount	0		3,931
Mortgages and other debts payable	3,350		5,150
Deferred tax liabilities	164,892		9,777
Other, including deferred revenue	1,006		380
Other long-term liabilities	234,762	[1]	34,168	[1]
Cytochroma [Member]	'		'
Other long-term liabilities:	'		'
Contingent consideration	51,447		0
Farmadiet [Member]	'		'
Other long-term liabilities:	'		'
Contingent consideration	542		532
OPKO Diagnostics [Member]	'		'
Other long-term liabilities:	'		'
Contingent consideration	12,976		11,310
FineTech [Member]	'		'
Other long-term liabilities:	'		'
Contingent consideration	0		2,578
CURNA [Member]	'		'
Other long-term liabilities:	'		'
Contingent consideration	549		510
Technologies [Member]	'		'
Intangible assets, net:	'		'
Intangible assets	52,947		52,810
Customer relationships [Member]	'		'
Intangible assets, net:	'		'
Intangible assets	22,883		23,088
Product registrations [Member]	'		'
Intangible assets, net:	'		'
Intangible assets	9,861		9,637
Tradenames [Member]	'		'
Intangible assets, net:	'		'
Intangible assets	3,702		3,746
Covenants not to compete [Member]	'		'
Intangible assets, net:	'		'
Intangible assets	8,667		8,662
Other [Member]	'		'
Intangible assets, net:	'		'
Intangible assets	$1,177		$367
[1]	As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Acquisitions_Investments_and_L2

Acquisitions, Investments, and Licenses - Summary of Assets Acquired and Liabilities Assumed (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Aug. 29, 2013

Aug. 29, 2013

Aug. 29, 2013

Cytochroma acquisition [Member]

Cytochroma acquisition [Member]

Cytochroma acquisition [Member]

PROLOR [Member]

PROLOR [Member]

PROLOR [Member]

Patents [Member]

In Process Research and Development [Member]

Patents [Member]

In Process Research and Development [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

Current assets

'

'

$1,224,000

[1]

'

'

$21,500,000

[1]

'

'

Intangible assets:

'

'

'

'

'

'

'

'

In-process research and development

'

'

'

'

191,530,000

'

'

590,200,000

Patents

'

'

'

210,000

'

'

0

'

Total intangible assets

'

'

191,740,000

'

'

590,200,000

'

'

Goodwill

222,340,000

[2]

80,450,000

[2]

2,411,000

'

'

139,784,000

'

'

Property, plant and equipment

'

'

306,000

'

'

1,057,000

'

'

Other assets

'

'

0

'

'

371,000

'

'

Accounts payable and accrued expenses

'

'

-1,069,000

'

'

-9,866,000

'

'

Business Acquisition, Purchase Price Allocation, Deferred Taxes Asset (Liability), Net, Noncurrent

'

'

0

'

'

-156,403,000

'

'

Total purchase price

'

'

194,612,000

'

'

586,643,000

'

'

Current Asset include cash

'

'

$400,000

'

'

$20,500,000

'

'

[1]

Current assets include cash of $0.4 million and $20.5 million related to the Cytochroma and PROLOR acquisitions, respectively

[2]

As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Acquisitions_Investments_and_L3

Acquisitions, Investments, and Licenses - Summary of Pro Forma Results (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Pro Forma Result of Combined Companies	'	'	'	'
Revenues	$20,641	$13,976	$75,838	$37,327
Net loss	-75,858	-15,745	130,118	-43,864
Net loss attributable to common shareholders	($75,055)	($16,302)	($128,229)	($45,534)
Basic and diluted loss per share (in dollars per share)	($0.19)	($0.04)	($0.32)	($0.12)

Acquisitions_Investments_and_L4

Acquisitions, Investments, and Licenses - Summary of Investments (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Investment [Line Items]	'		'
Investment, available for sale	$29,005		$5,335
Plus unrealized/realized gains on investments, options and warrants, net	2,708		'
Less accumulated losses in investees	-12,579		'
Investments, net	24,690	[1]	15,636	[1]
Sorrento [Member]	'		'
Investment [Line Items]	'		'
Ownership at September 30, 2013	14.00%		'
Investment, equity method	2,300		'
Underlying equity in net assets	821		'
Cocrystal [Member]	'		'
Investment [Line Items]	'		'
Ownership at September 30, 2013	16.00%		'
Investment, equity method	2,500		'
Underlying equity in net assets	358		'
Neovasc [Member]	'		'
Investment [Line Items]	'		'
Ownership at September 30, 2013	6.00%		'
Investment, equity method	3,798		'
Underlying equity in net assets	454		'
Fabrus [Member]	'		'
Investment [Line Items]	'		'
Ownership at September 30, 2013	13.00%		'
Investment, equity method	650		'
Underlying equity in net assets	-108		'
BZBE common stock [Member]	'		'
Investment [Line Items]	'		'
Ownership at September 30, 2013	11.00%		'
Investment, equity method	1,276		'
Underlying equity in net assets	-1,184		'
RXi [Member]	'		'
Investment [Line Items]	'		'
Ownership at September 30, 2013	19.00%		'
Investment, equity method	15,000		'
Underlying equity in net assets	2,847		'
Pharmasynthez [Member]	'		'
Investment [Line Items]	'		'
Ownership at September 30, 2013	11.00%		'
Investment, equity method	5,036		'
Underlying equity in net assets	5,156		'
TESARO [Member]	'		'
Investment [Line Items]	'		'
Ownership at September 30, 2013	1.00%		'
Investment, available for sale	56		'
Closing share price at September 30, 2013 for investments available for sale	$38.74		'
Neovasc Options [Member]	'		'
Investment [Line Items]	'		'
Investment, available for sale	925		'
Closing share price at September 30, 2013 for investments available for sale	$2.35		'
BZNE Note and conversion feature [Member]	'		'
Investment [Line Items]	'		'
Investment, available for sale	1,700		'
Closing share price at September 30, 2013 for investments available for sale	'		'
ChromaDex [Member]	'		'
Investment [Line Items]	'		'
Ownership at September 30, 2013	1.00%		'
Investment, available for sale	$1,320		'
Closing share price at September 30, 2013 for investments available for sale	$0.81		'
[1]	As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Acquisitions_Investments_and_L5

Acquisitions, Investments, and Licenses - Schedule of Consolidated Assets and Non-Recourse Liabilities (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012		Sep. 30, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Current assets:	'		'		'	'
Cash and cash equivalents	$155,834	[1]	$27,361	[1]	$23,428	$71,516
Accounts receivable, net	21,372	[1]	21,162	[1]	'	'
Inventory, net	19,516	[1]	22,261	[1]	'	'
Prepaid expenses and other current assets	19,551	[1]	7,873	[1]	'	'
Total current assets	241,277	[1]	78,657	[1]	'	'
Property, plant and equipment, net	17,027	[1]	16,526	[1]	'	'
Intangible assets, net	77,333	[1]	84,238	[1]	'	'
Goodwill	222,340	[1]	80,450	[1]	'	'
Other assets	7,003	[1]	2,777	[1]	'	'
Total assets	1,382,982	[1]	289,830	[1]	'	'
Current liabilities:	'		'		'	'
Accounts payable	13,631	[1]	10,200	[1]	'	'
Accrued expenses	43,269	[1]	24,656	[1]	'	'
Total current liabilities	71,377	[1]	52,382	[1]	'	'
Other long-term liabilities	234,762	[1]	34,168	[1]	'	'
Total liabilities	515,056	[1]	86,550	[1]	'	'
SciVac [Member] | Variable Interest Entity, Primary Beneficiary [Member]	'		'		'	'
Current assets:	'		'		'	'
Cash and cash equivalents	136		174		'	'
Accounts receivable, net	205		387		'	'
Inventory, net	1,653		1,092		'	'
Prepaid expenses and other current assets	185		199		'	'
Total current assets	2,179		1,852		'	'
Property, plant and equipment, net	1,410		1,539		'	'
Intangible assets, net	1,122		1,154		'	'
Goodwill	841		796		'	'
Other assets	312		231		'	'
Total assets	5,864		5,572		'	'
Current liabilities:	'		'		'	'
Accounts payable	1,129		1,108		'	'
Accrued expenses	5,969		2,859		'	'
Notes payable	1,284		0		'	'
Total current liabilities	8,382		3,967		'	'
Other long-term liabilities	279		1,529		'	'
Total liabilities	$8,661		$5,496		'	'
[1]	As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Acquisitions_Investments_and_L6

Acquisitions, Investments, and Licenses - Textual (Details)

3 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Jun. 30, 2012

Sep. 30, 2013

Aug. 31, 2011

Sep. 30, 2013

Apr. 30, 2013

Apr. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Aug. 29, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Feb. 28, 2013

Dec. 31, 2012

Aug. 29, 2013

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Aug. 29, 2013

Aug. 31, 2012

Aug. 29, 2013

Aug. 29, 2013

Aug. 31, 2012

Aug. 31, 2012

Sep. 30, 2013

Apr. 30, 2012

USD ($)

USD ($)

USD ($)

USD ($)

SciVac [Member]

SciVac [Member]

Neovasc [Member]

Neovasc [Member]

Pharmsynthez [Member]

Pharmsynthez [Member]

Pharmsynthez [Member]

Pharmsynthez [Member]

RXi Pharmaceuticals Corporation [Member]

RXi Pharmaceuticals Corporation [Member]

PROLOR [Member]

PROLOR [Member]

Cytochroma acquisition [Member]

Cytochroma acquisition [Member]

OPKO Brazil [Member]

OURLab [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

ALS Acquisition [Member]

ALS Acquisition [Member]

ALS Acquisition [Member]

Variable Interest Entity, Primary Beneficiary [Member]

Variable Interest Entity, Primary Beneficiary [Member]

USD ($)

USD ($)

USD ($)

RUB

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

Ancillary Transaction One [Member]

Ancillary Transaction One [Member]

Ancillary Transaction Two [Member]

Ancillary Transaction Two [Member]

Ancillary Transaction Two [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Transaction

USD ($)

EUR (€)

USD ($)

member

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares conversion ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.9951

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Delivery of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

63,670,805

'

20,517,030

'

64,684

7,072,748

'

585,703

'

'

'

'

125,000

'

70,421

70,421

'

'

'

'

Business Acquisition, Equity Interest Issued or Issuable, Value Assigned

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$540,600,000

'

$146,900,000

'

$400,000

$32,900,000

'

'

'

'

'

'

'

'

'

'

$300,000

'

'

'

Share price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.49

$8.49

$7.16

'

$6.73

$4.65

'

'

'

'

$7.52

'

'

'

'

'

'

'

'

'

Options and warrants outstanding (shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,889,265

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

46,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of ownership held by chairman

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of ownership held by directors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of trading days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 days

'

'10 days

'15 days

'10 days

'10 days

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition share price on shares issue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.87

'

$4.64

$4.33

'

$7.61

'

'

'

'

'

'

'

'

'

'

'

'

Amount payable in cash or shares on achieving milestones for acquiring a product in development

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

190,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

Contingent consideration

69,200,000

69,200,000

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

47,700,000

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

Cash paid at closing date

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

9,400,000

'

'

8,400,000

'

'

'

'

'

'

'

'

2,400,000

800,000

'

Aggregate purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,000,000

13,500,000

'

'

'

'

1,300,000

1,000,000

'

4,000,000

'

'

Stock consideration issued in the transaction is being held in a separate escrow account to secure the indemnification obligations of OURLab

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,732,102

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid at closing date percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

50.00%

'

'

'

'

'

'

25.00%

'

'

'

Percentage of deferred payment paid at our option in cash or shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

50.00%

'

'

'

'

'

'

'

'

'

'

Percentage of paid on first anniversary of closing date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

25.00%

'

'

'

'

'

'

'

'

'

'

Paid in eighteen months after closing date in percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

25.00%

'

'

'

'

'

'

'

'

'

'

Deferred acquisition payments

5,335,000

5,335,000

'

6,172,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,800,000

6,800,000

'

'

'

'

'

'

'

'

'

'

Deferred acquisition payments discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

Deferred Payment to satisfy indemnify claims

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,600,000

2,800,000

'

'

'

'

'

'

'

'

Number of ancillary transactions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

Percentage for ancillary transaction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40.00%

'

'

'

'

'

'

'

Issue of common stock / Issue of common stock against acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

Number of shares issued upon achieving certain milestone

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000

'

'

'

'

'

'

Percentage of amount payable on cash or shares on achieving certain milestone

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75.00%

'

'

'

Purchase Consideration in cash at closing into a separate escrow account

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

15,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Invested in common shares

'

'

'

'

'

'

2,000,000

1,200,000

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares purchased

'

'

'

'

'

'

2,000,000

'

13,600,000

13,600,000

'

'

17,241,380

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expiration period

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase common shares

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment Warrants, Exercise Price

'

'

'

'

'

'

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset Purchase Agreement

'

'

'

'

'

'

'

'

9,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of share options received in purchase agreement

'

'

'

'

'

'

'

'

12,000,000

12,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue

7,900,000

7,900,000

'

1,900,000

'

'

'

'

9,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds to be received from sale of proprietary technology

'

'

'

'

'

'

'

'

8,100,000

265,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for development of technology

'

'

'

'

'

'

'

'

'3 years

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from collection of notes feceivable

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue received from collaboration agreement

3,400,000

'

'

'

'

'

'

'

'

'

'

6,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue related to our license agreements

'

'

'

'

'

'

'

'

'

'

1,300,000

3,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue collaboration agreement, offset to research and development

400,000

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issue of common stock shares

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue related to sale of intellectual property

'

12,500,000

0

'

'

'

'

'

'

'

'

'

'

12,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone payments

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset purchase agreement financing for Rxi

'

'

'

'

'

'

'

'

'

'

'

'

'

16,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cocrystal on a fully diluted basis

'

'

'

'

45.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional working capital

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of members of board of directors

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of members of board of directors appointed by reporting entity

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percent of board of directors appointed by reporting entity

'

'

'

'

60.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total assets of equity method investees

105,500,000

105,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total liabilities of equity method investees

39,600,000

39,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net losses of equity method investees

'

($51,200,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt_Notes_Details

Debt - Notes (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Jan. 30, 2013
					Notes [Member]	Notes [Member]
Debt Instrument [Roll Forward]	'	'	'	'	'	'
Embedded derivatives, beginning balance	'	'	'	'	'	$59,204
Convertible notes, beginning balance	'	'	'	'	'	175,000
Discount, beginning balance	'	'	'	'	'	-59,204
Total, beginning balance	'	'	'	'	'	175,000
Amortization of debt discount	'	'	'	'	4,866	'
Debt discount write-off associated with conversion of debt	'	'	'	'	5,368	'
Change in fair value of embedded derivative	-27,793	169	-38,691	1,309	41,818	'
Embedded derivative, conversion	'	'	'	'	-1,199	'
Convertible notes, conversion	'	'	'	'	-16,936	'
Total, conversion	'	'	'	'	-18,135	'
Embedded derivatives, ending balance	'	'	'	'	99,823	59,204
Convertible notes, ending balance	'	'	'	'	158,064	175,000
Discount, ending balance	'	'	'	'	-48,970	-59,204
Total, ending balance	'	'	'	'	$208,917	$175,000

Debt_Inputs_Used_In_Lattice_Mo

Debt - Inputs Used In Lattice Model (Details) (Notes [Member], Notes Due February 1, 2033 [Member], USD $)	0 Months Ended	1 Months Ended	9 Months Ended
	Aug. 29, 2013	Jan. 30, 2013	Sep. 30, 2013
		Rate	Rate
Notes [Member] | Notes Due February 1, 2033 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Share price	'	$6.20	$8.81
Conversion Rate	141.4827	141.4827	141.4827
Conversion Price	'	$7.07	$7.07
Maturity date	'	1-Feb-33	1-Feb-33
Risk-free interest rate	'	1.12%	1.50%
Estimated stock volatility	'	40.00%	40.00%
Estimated credit spread	'	9.44%	9.48%

Debt_Fair_Value_Of_Embedded_De

Debt - Fair Value Of Embedded Derivatives (Details) (Notes [Member], USD $)	Sep. 30, 2013	Jan. 30, 2013
In Thousands, unless otherwise specified
Notes [Member]	'	'
Fair value of Notes:	'	'
With the embedded derivatives	$210,105	$175,000
Without the embedded derivatives	110,282	115,796
Estimated fair value of the embedded derivatives	$99,823	$59,204

Debt_Lines_Of_Credit_Details

Debt - Lines Of Credit (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Line of Credit Facility [Line Items]	'	'
Credit line capacity	$16,991,000	'
Balance outstanding	11,397,000	15,195,000
Itau Bank [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	8.04%	'
Credit line capacity	3,000,000	'
Balance outstanding	2,207,000	2,738,000
Bank of Chile [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	7.80%	'
Credit line capacity	3,000,000	'
Balance outstanding	1,967,000	2,292,000
BICE Bank [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	5.50%	'
Credit line capacity	1,500,000	'
Balance outstanding	867,000	2,451,000
Corp Banca [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	5.50%	'
Credit line capacity	0	'
Balance outstanding	28,000	1,248,000
BBVA Bank [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	8.29%	'
Credit line capacity	2,500,000	'
Balance outstanding	1,230,000	2,823,000
Penta Bank [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	9.48%	'
Credit line capacity	800,000	'
Balance outstanding	992,000	833,000
Security Bank [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	7.56%	'
Credit line capacity	1,500,000	'
Balance outstanding	1,063,000	0
BCI [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	5.50%	'
Credit line capacity	1,000,000	'
Balance outstanding	1,216,000	0
Estado Bank [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	6.88%	'
Credit line capacity	2,000,000	'
Balance outstanding	1,732,000	1,963,000
Sabadell Bank [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	7.60%	'
Credit line capacity	203,000	'
Balance outstanding	0	3,000
Bilbao Vizcaya Bank [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	4.90%	'
Credit line capacity	406,000	'
Balance outstanding	91,000	377,000
Banco Popular [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	8.25%	'
Credit line capacity	406,000	'
Balance outstanding	0	260,000
Santander Bank [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	6.00%	'
Credit line capacity	203,000	'
Balance outstanding	0	0
Banesto [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	5.80%	'
Credit line capacity	203,000	'
Balance outstanding	4,000	163,000
Banca March [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Interest rate on borrowings	6.25%	'
Credit line capacity	270,000	'
Balance outstanding	$0	$44,000

Debt_Mortgage_Notes_And_Other_

Debt - Mortgage Notes And Other Debt (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Mortgage notes and other debt payables	'		'
Current portion of lines of credit and notes payable	$14,477	[1]	$17,526	[1]
Mortgages and other debts payable	3,350		5,150
Farmadiet Acquisition [Member]	'		'
Mortgage notes and other debt payables	'		'
Current portion of lines of credit and notes payable	1,796		2,331
Mortgages and other debts payable	3,350		3,916
Total mortgage notes and other debt payables	$5,146		$6,247
[1]	As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Debt_Textual_Details

Debt - Textual (Details) (USD $)

9 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jan. 30, 2013

Aug. 29, 2013

Jan. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

institution

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Minimum [Member]

Maximum [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Line of Credit [Member]

Line of Credit [Member]

Farmadiet Acquisition [Member]

Farmadiet Acquisition [Member]

Notes Due February 1, 2033 [Member]

Notes Due February 1, 2033 [Member]

Notes Due February 1, 2033 [Member]

Notes Due February 1, 2033 [Member]

Notes Due February 1, 2033 [Member]

Notes Due February 1, 2033 [Member]

Notes Due February 1, 2033 [Member]

Notes Due February 1, 2033 [Member]

conversion_right

Rate

Rate

Minimum [Member]

Maximum [Member]

On or after February 1, 2017 and before February 1, 2019 [Member]

On or after February 1, 2019 [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal balance

'

'

$5,146,000

$6,247,000

'

'

$208,917,000

$175,000,000

'

'

$158,100,000

'

'

'

'

'

'

'

Debt face amount

'

'

'

'

'

'

'

'

'

175,000,000

'

'

'

'

'

'

'

'

Interest rate of notes payable

3.00%

'

'

'

'

'

'

'

'

3.00%

3.00%

3.00%

'

'

'

'

'

'

Equivalent redemption price

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

100.00%

100.00%

'

'

Convertible debt, conversion ratio

'

'

'

'

'

'

'

'

141.4827

141.4827

141.4827

'

'

'

'

'

'

'

Convertible debt, principal amount for conversion

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

Loss on conversion of 3.00% convertible senior notes

-8,688,000

0

'

'

'

'

'

'

8,700,000

'

'

'

'

'

'

'

'

'

Convertible debt, conversion price

'

'

'

'

'

'

'

'

'

$7.07

$7.07

'

'

'

'

'

'

'

Convertible debt, conversion right triggered

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

Convertible debt, threshold percentage of stock price trigger

'

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

Convertible debt, converted amount

'

0

'

'

'

'

'

'

16,900,000

'

20,839,000

'

'

'

'

'

'

'

Convertible debt, stock issued from conversion

'

'

'

'

'

'

'

'

2,396,145

'

'

'

'

'

'

'

'

'

Number of trading days applicable conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

Number of consecutive trading days applicable conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

Gain (loss) on embedded derivative

$41,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of financial institutions

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average interest rate

'

'

4.20%

4.50%

'

'

'

'

'

'

'

'

'

'

'

'

7.40%

6.50%

Variable interest rates

'

'

'

'

2.70%

6.30%

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012		Sep. 30, 2013		Sep. 30, 2013
In Thousands, unless otherwise specified					Accumulated Translation Adjustment [Member]		Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Net [Rollforward]	'		'		'		'
Beginning Balance	$3,237	[1]	$7,356	[1]	$3,196		$4,160
Other comprehensive income before reclassifications, net of tax	'		'		-1,395	[2]	1,869	[2]
Amounts reclassified from accumulated other comprehensive income, net of tax	'		'		0	[2]	-4,593	[2]
Net other comprehensive income	'		'		-1,395		-2,724
Ending Balance	$3,237	[1]	$7,356	[1]	$1,801		$1,436
[1]	As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.
[2]	Effective tax rate of 38.47%.

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Details Textual) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Equity [Abstract]	'
Effective tax rate	38.47%
Realized gain	$10.80
Unrealized gain reclassified	$7.50

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary Of Investments (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$29,005	$5,335
Gross unrealized gains in Accumulated OCI	2,184	6,725
Gross unrealized losses in Accumulated OCI	-202	0
Gain/(Loss) in Accumulated Deficit	468	88
Fair value	31,455	12,148
Common Stock [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	1,376	2,051
Gross unrealized gains in Accumulated OCI	1,417	6,185
Gross unrealized losses in Accumulated OCI	0	0
Gain/(Loss) in Accumulated Deficit	'	'
Fair value	2,793	8,236
BZNE Note and conversion feature [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	1,700	1,700
Gross unrealized gains in Accumulated OCI	53	53
Gross unrealized losses in Accumulated OCI	0	0
Gain/(Loss) in Accumulated Deficit	287	287
Fair value	2,040	2,040
Neovasc common stock options [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	925	925
Gross unrealized gains in Accumulated OCI	714	293
Gross unrealized losses in Accumulated OCI	-202	0
Gain/(Loss) in Accumulated Deficit	181	176
Fair value	1,618	1,394
Neovasc common stock warrants [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	'	659
Gross unrealized gains in Accumulated OCI	'	194
Gross unrealized losses in Accumulated OCI	'	0
Gain/(Loss) in Accumulated Deficit	'	-375
Fair value	'	478
US Treasury Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	25,004	'
Gross unrealized gains in Accumulated OCI	0	'
Gross unrealized losses in Accumulated OCI	'	'
Gain/(Loss) in Accumulated Deficit	0	'
Fair value	$25,004	'

Fair_Value_Measurements_Assets

Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Level 1 [Member]	'	'
Assets:	'	'
Total assets	$119,270	$26,952
Level 2 [Member]	'	'
Assets:	'	'
Total assets	34,204	2,692
Liabilities:	'	'
Total liabilities	-25	10
Level 3 [Member]	'	'
Assets:	'	'
Total assets	2,040	2,040
Liabilities:	'	'
Total liabilities	174,367	30,159
Estimate of Fair Value Measurement [Member]	'	'
Assets:	'	'
Total assets	155,514	31,684
Liabilities:	'	'
Total liabilities	174,342	30,169
Forward contracts [Member] | Level 2 [Member]	'	'
Liabilities:	'	'
Total liabilities	-25	10
Forward contracts [Member] | Estimate of Fair Value Measurement [Member]	'	'
Liabilities:	'	'
Total liabilities	-25	10
Embedded conversion option [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Total liabilities	99,823	'
Embedded conversion option [Member] | Estimate of Fair Value Measurement [Member]	'	'
Liabilities:	'	'
Total liabilities	99,823	'
Deferred acquisition payments, net of discount [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Total liabilities	5,335	10,103
Deferred acquisition payments, net of discount [Member] | Estimate of Fair Value Measurement [Member]	'	'
Liabilities:	'	'
Total liabilities	5,335	10,103
Contingent consideration [Member] | CURNA [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Total liabilities	549	510
Contingent consideration [Member] | CURNA [Member] | Estimate of Fair Value Measurement [Member]	'	'
Liabilities:	'	'
Total liabilities	549	510
Contingent consideration [Member] | Opko Diagnostics [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Total liabilities	12,976	12,974
Contingent consideration [Member] | Opko Diagnostics [Member] | Estimate of Fair Value Measurement [Member]	'	'
Liabilities:	'	'
Total liabilities	12,976	12,974
Contingent consideration [Member] | FineTech [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Total liabilities	2,862	5,262
Contingent consideration [Member] | FineTech [Member] | Estimate of Fair Value Measurement [Member]	'	'
Liabilities:	'	'
Total liabilities	2,862	5,262
Contingent consideration [Member] | Cytochroma [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Total liabilities	51,447	'
Contingent consideration [Member] | Cytochroma [Member] | Estimate of Fair Value Measurement [Member]	'	'
Liabilities:	'	'
Total liabilities	51,447	'
Contingent consideration [Member] | Farmadiet [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Total liabilities	1,375	1,310
Contingent consideration [Member] | Farmadiet [Member] | Estimate of Fair Value Measurement [Member]	'	'
Liabilities:	'	'
Total liabilities	1,375	1,310
Money market funds [Member] | Level 1 [Member]	'	'
Assets:	'	'
Total assets	116,477	18,716
Money market funds [Member] | Estimate of Fair Value Measurement [Member]	'	'
Assets:	'	'
Total assets	116,477	18,716
US Treasury Securities [Member] | Level 1 [Member]	'	'
Assets:	'	'
Total assets	0	'
US Treasury Securities [Member] | Level 2 [Member]	'	'
Assets:	'	'
Total assets	25,004	'
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Assets:	'	'
Total assets	25,004	'
Certificates of Deposit [Member] | Level 2 [Member]	'	'
Assets:	'	'
Total assets	827	820
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member]	'	'
Assets:	'	'
Total assets	827	820
Notes Receivable [Member] | Level 2 [Member]	'	'
Assets:	'	'
Total assets	6,755	'
Notes Receivable [Member] | Estimate of Fair Value Measurement [Member]	'	'
Assets:	'	'
Total assets	6,755	'
Common Stock [Member] | Level 1 [Member]	'	'
Assets:	'	'
Total assets	2,793	8,236
Common Stock [Member] | Estimate of Fair Value Measurement [Member]	'	'
Assets:	'	'
Total assets	2,793	8,236
BZNE Note and conversion feature [Member] | Level 3 [Member]	'	'
Assets:	'	'
Total assets	2,040	2,040
BZNE Note and conversion feature [Member] | Estimate of Fair Value Measurement [Member]	'	'
Assets:	'	'
Total assets	2,040	2,040
Neovasc common stock options [Member] | Level 2 [Member]	'	'
Assets:	'	'
Total assets	1,618	1,394
Neovasc common stock options [Member] | Estimate of Fair Value Measurement [Member]	'	'
Assets:	'	'
Total assets	1,618	1,394
Neovasc common stock warrants [Member] | Level 2 [Member]	'	'
Assets:	'	'
Total assets	'	478
Neovasc common stock warrants [Member] | Estimate of Fair Value Measurement [Member]	'	'
Assets:	'	'
Total assets	'	$478

Fair_Value_Measurements_Notes_

Fair Value Measurements - Notes (Details) (Notes [Member], USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Estimate of Fair Value Measurement [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Notes	$110,282
Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Notes	'
Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Notes	'
Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Notes	110,282
Carrying Value [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Notes	$109,094

Fair_Value_Measurements_Level_

Fair Value Measurements - Level 3 Reconciliation (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Contingent consideration [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'
Beginning Balance, liabilities	$20,056	$18,002
Additions, liabilities	47,710	1,234
Total losses (gains) for the period:	'	'
Included in results of operations, liabilities	4,204	820
Payments/conversions, liabilities	-2,761	'
Ending Balance, liabilities	69,209	20,056
Deferred acquisition payments, net of discount [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'
Beginning Balance, liabilities	10,103	0
Additions, liabilities	'	9,673
Total losses (gains) for the period:	'	'
Included in results of operations, liabilities	597	430
Payments/conversions, liabilities	-5,365	'
Ending Balance, liabilities	5,335	10,103
Embedded conversion option [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'
Beginning Balance, liabilities	0	'
Additions, liabilities	59,204	'
Total losses (gains) for the period:	'	'
Included in results of operations, liabilities	41,818	'
Payments/conversions, liabilities	-1,199	'
Ending Balance, liabilities	99,823	'
BZNE Note and conversion feature [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'
Beginning Balance, assets	'	0
Additions, assets	'	1,700
Total losses (gains) for the period:	'	'
Included in results of operations, assets	'	1,563
Included in Other comprehensive loss, assets	'	53
Transfer out to equity method investment, assets	'	1,276
Ending Balance, assets	$2,040	$2,040

Fair_Value_Measurements_Textua

Fair Value Measurements - Textual (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
US treasury securities	$25	'
Change in contingent consideration on discount rates increase	2	'
Decrease of estimated future sales in amount	0.8	'
Contingent consideration	69.2	20
Maximum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Discount rates related to consideration	27.00%	'
Minimum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Discount rates related to consideration	6.00%	'
Accrued Liabilities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent consideration	3.7	5.1
Other Noncurrent Liabilities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent consideration	$65.50	$14.90

Derivative_Contracts_Details

Derivative Contracts (Details) (USD $)	Sep. 30, 2013		Jan. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'		'	'
Convertible senior notes interest rate	3.00%		'	'
Notes [Member] | Notes Due February 1, 2033 [Member]	'		'	'
Derivatives, Fair Value [Line Items]	'		'	'
Convertible senior notes interest rate	3.00%		3.00%	3.00%
Not Designated as Hedging Instrument [Member] | Pharmsynthez Notes Receivable and Purchase Option [Member] | Prepaid expenses and other current assets [Member]	'		'	'
Derivatives, Fair Value [Line Items]	'		'	'
Derivative asset, fair value	6,755		'	0
Not Designated as Hedging Instrument [Member] | Neovasc common stock options/warrants [Member] | Investments, net [Member]	'		'	'
Derivatives, Fair Value [Line Items]	'		'	'
Derivative asset, fair value	1,618		'	1,872
Not Designated as Hedging Instrument [Member] | Embedded conversion option [Member] | 3.00% convertible, senior notes, net of discount and estimated fair value of embedded derivatives [Member]	'		'	'
Derivatives, Fair Value [Line Items]	'		'	'
Derivative liability, fair value	99,823		'	0
Not Designated as Hedging Instrument [Member] | Forward contracts [Member]	'		'	'
Derivatives, Fair Value [Line Items]	'		'	'
Derivative liability, fair value	3,899		'	1,294
Not Designated as Hedging Instrument [Member] | Forward contracts [Member] | Current portion of lines of credit and notes payable [Member]	'		'	'
Derivatives, Fair Value [Line Items]	'		'	'
Derivative liability, fair value	3,899	[1]	'	1,294	[1]
[1]	The effect on loss in the forward contracts is recorded in Accrued expenses. The effect on income in the forward contracts is recorded in Prepaid expenses and other current assets.

Derivative_Contracts_Details_1

Derivative Contracts (Details 1) (Not Designated as Hedging Instrument [Member], USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'	'
Total	($27,793)	$169	($38,691)	$1,309	'
Pharmsynthez Notes Receivable and Purchase Option [Member]	'	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'	'
Total	-147	0	2,452	0	'
Neovasc common stock options/warrants and BZNE Note conversion feature [Member]	'	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'	'
Total	-545	201	700	1,368	'
Notes [Member]	'	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'	'
Total	-26,943	'	-41,818	'	'
Forward contracts [Member]	'	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'	'
Total	($158)	($32)	($25)	($59)	($10)

Derivative_Contracts_Details_2

Derivative Contracts (Details 2) (Not Designated as Hedging Instrument [Member], USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Derivative [Line Items]	'	'	'	'	'
Derivative, Gain (Loss) on Derivative, Net	($27,793)	$169	($38,691)	$1,309	'
Forward Contracts [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Contract value	3,924	'	3,924	'	1,304
Fair value	3,899	'	3,899	'	1,294
Derivative, Gain (Loss) on Derivative, Net	-158	-32	-25	-59	-10
Forward Contracts [Member] | 0 to 30 [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Contract value	1,133	'	1,133	'	'
Fair value	1,139	'	1,139	'	'
Derivative, Gain (Loss) on Derivative, Net	'	'	6	'	0
Contract days until maturity, lower range	'	'	'0 days	'	'0 days
Contract days until maturity, higher range	'	'	'30 days	'	'30 days
Forward Contracts [Member] | 31 to 60 [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Contract value	1,058	'	1,058	'	581
Fair value	1,039	'	1,039	'	577
Derivative, Gain (Loss) on Derivative, Net	'	'	-19	'	-4
Contract days until maturity, lower range	'	'	'31 days	'	'31 days
Contract days until maturity, higher range	'	'	'60 days	'	'60 days
Forward Contracts [Member] | 61 to 90 [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Contract value	945	'	945	'	341
Fair value	939	'	939	'	339
Derivative, Gain (Loss) on Derivative, Net	'	'	-6	'	-2
Contract days until maturity, lower range	'	'	'61 days	'	'61 days
Contract days until maturity, higher range	'	'	'90 days	'	'90 days
Forward Contracts [Member] | 91 to 120 [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Contract value	272	'	272	'	212
Fair value	271	'	271	'	210
Derivative, Gain (Loss) on Derivative, Net	'	'	-1	'	-2
Contract days until maturity, lower range	'	'	'91 days	'	'91 days
Contract days until maturity, higher range	'	'	'120 days	'	'120 days
Forward Contracts [Member] | 121 to 180 [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Contract value	516	'	516	'	170
Fair value	511	'	511	'	168
Derivative, Gain (Loss) on Derivative, Net	'	'	-5	'	-2
Contract days until maturity, lower range	'	'	'121 days	'	'121 days
Contract days until maturity, higher range	'	'	'180 days	'	'180 days
Forward Contracts [Member] | More than 180 [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Contract value	0	'	0	'	0
Fair value	0	'	0	'	'
Derivative, Gain (Loss) on Derivative, Net	'	'	$0	'	$0
Contract days until maturity, higher range	'	'	'180 days	'	'180 days

Related_Party_Transactions_Tex

Related Party Transactions - Textual (Details) (USD $)

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

Feb. 29, 2012

Feb. 29, 2012

Nov. 30, 2010

Sep. 21, 2009

Sep. 30, 2009

Sep. 30, 2009

Jan. 30, 2013

Sep. 21, 2011

Aug. 31, 2011

Sep. 21, 2011

Aug. 29, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 21, 2011

Aug. 31, 2011

Sep. 21, 2011

Aug. 29, 2013

Aug. 31, 2011

Sep. 21, 2011

Aug. 29, 2013

Jan. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Feb. 29, 2012

Feb. 29, 2012

Sep. 30, 2012

Apr. 30, 2012

Feb. 29, 2012

Nov. 30, 2010

Jun. 30, 2009

Sep. 21, 2011

16-May-11

Sep. 21, 2011

Sep. 21, 2011

Nov. 30, 2010

Jun. 30, 2010

Sep. 30, 2009

Aug. 31, 2012

Nov. 30, 2007

Chromadex Corporation [Member]

Biozone Pharmaceuticals Inc [Member]

Fabrus Inc [Member]

Cocrystal [Member]

Cocrystal [Member]

Convertible Preferred Stock [Member]

Notes [Member]

Dr Frost [Member]

Dr Frost [Member]

Dr Frost [Member]

Dr Frost [Member]

Dr Frost [Member]

Dr Frost [Member]

Dr Frost [Member]

Dr Frost [Member]

Dr. Hsiao [Member]

Dr. Hsiao [Member]

Dr. Hsiao [Member]

Dr. Hsiao [Member]

Mr. Rubin [Member]

Mr. Rubin [Member]

Mr. Rubin [Member]

Frost Gamma Investments Trust and Hsu Gamma Investment, L.P. [Member]

Avi Properties LLC [Member]

Teva [Member]

Scripps Research Institute [Member]

Gamma Trust [Member]

Gamma Trust [Member]

Gamma Trust [Member]

Hsu Gamma [Member]

Dr. Lerner [Member]

Dr. Lerner [Member]

Aero Pharmaceuticals Inc [Member]

Aero Pharmaceuticals Inc [Member]

Mr. Prego Novo [Member]

Mr. Prego Novo [Member]

Gamma Trust and Hsu Gamma [Member]

Academia Sinica [Member]

Frost Group, LLC [Member]

Real Estate Holdings LLC [Member]

Real Estate Holdings LLC [Member]

Notes Due February 1, 2033 [Member]

Biozone Pharmaceuticals Inc [Member]

PROLOR [Member]

Reimbursement Of Travel Expense [Member]

Reimbursement Of Travel Expense [Member]

Reimbursement Of Travel Expense [Member]

Reimbursement Of Travel Expense [Member]

Biozone Pharmaceuticals Inc [Member]

PROLOR [Member]

Biozone Pharmaceuticals Inc [Member]

PROLOR [Member]

Notes [Member]

sqft

FineTech [Member]

Chromadex Corporation [Member]

Biozone Pharmaceuticals Inc [Member]

Biozone Pharmaceuticals Inc [Member]

Chromadex Corporation [Member]

Fabrus Inc [Member]

Sorrento [Member]

Biozone Pharmaceuticals Inc [Member]

Biozone Pharmaceuticals Inc [Member]

Biozone Pharmaceuticals Inc [Member]

Fabrus Inc [Member]

Installment

sqft

Notes Due February 1, 2033 [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beneficially owned held by members

'

'

13.00%

'

'

'

'

46.00%

36.00%

9.20%

5.00%

'

'

'

'

12.00%

6.00%

1.70%

5.00%

1.00%

1.00%

5.00%

'

'

'

'

16.00%

'

'

1.00%

'

'

'

'

23.00%

8.20%

'

'

'

'

'

Debt face amount

'

'

'

'

'

'

$175,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$175,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of lease

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Square feet of laboratory

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,300

Payments of lease per month

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,000

Exceeds consumer price index

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of API to TEVA

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fund for research agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research agreement maturity period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Approximate funding for development of technology

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for development of technology

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beneficially owned held by owners

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Invested in common shares

1,000,000

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible senior notes interest rate

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Par value

'

$0.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants duration

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase common shares

'

8,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price per share

'

$0.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issue of common stock / Issue of common stock against acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13,914

8,331,396

'

'

'

'

'

'

'

Loan to bzne

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

Investment was part of financing for Fabrus

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

'

'

'

'

Ownership percentage held by director

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

Research and development agreement amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

Invested in common shares

'

'

'

2,500,000

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,300,000

'

'

'

'

'

'

'

'

'

Equity method investment, number of shares purchased

'

'

'

'

'

1,701,723

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Previous investment by a group of investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

Additional investment by a group of investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

Number of equal installments payable for additional investment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

Lease rent per month for fifth year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24,000

Credit for tenant improvements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

Period of lease agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

Reimbursement paid to related party for travel

'

'

'

'

'

'

'

'

'

'

'

$19,000

$52,000

$37,000

$181,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	1 Months Ended							0 Months Ended	1 Months Ended
	Jul. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	6-May-13	Nov. 30, 2012
	claim			Accrued Liabilities [Member]	Accrued Liabilities [Member]	Other Noncurrent Liabilities [Member]	Other Noncurrent Liabilities [Member]	Pending Litigation [Member]	Pending Litigation [Member]
								PROLOR Biotech, Inc. Shareholders' Litigation [Member]	Adrian Golstein, M.D., Former Employee of OURLab [Member]
								Suit
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'	'
Number of putative class action suits filed	'	'	'	'	'	'	'	5	'
Recovery of compensatory damages	'	'	'	'	'	'	'	'	$20,000,000
Number of claims included in post-payment audit	183	'	'	'	'	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'	'	'	'	'	'
Contingent consideration	'	$69,200,000	$20,000,000	$3,700,000	$5,100,000	$65,500,000	$14,900,000	'	'

Segments_Details

Segments (Details) (USD $)	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2012	Dec. 31, 2012
Segment Reporting Information [Line Items]	'		'	'		'	'
Product revenues	$16,563		$11,495	$50,708		$30,051	'
Revenue from services	2,770		100	9,050		332	'
Revenue from transfer of intellectual property	1,308		200	16,080		400	'
Operating (loss) income	-19,010		-9,369	-43,766		-27,557	'
Depreciation and amortization	3,768		2,665	10,648		7,447	'
Total revenues	20,641		11,795	75,838		30,783	'
Assets	1,382,982	[1]	'	1,382,982	[1]	'	289,830	[1]
Goodwill	222,340	[1]	'	222,340	[1]	'	80,450	[1]
United States [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Total revenues	4,078		300	25,130		732	'
Chile [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Total revenues	7,993		6,781	24,216		19,669	'
Spain [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Total revenues	4,026		1,997	13,503		1,997	'
Israel [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Total revenues	3,099		1,516	9,666		4,661	'
Mexico [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Total revenues	1,445		1,201	3,323		3,724	'
Corporate, Non-Segment [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Product revenues	'		'	'		'	'
Revenue from services	60		57	180		159	'
Revenue from transfer of intellectual property	0		0	0		0	'
Operating (loss) income	-6,606		-3,804	-17,393		-9,650	'
Depreciation and amortization	31		44	121		132	'
Assets	180,598		'	180,598		'	35,109
Goodwill	'		'	'		'	'
Segment Reconciling Items [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Operating (loss) income	-879		0	-2,419		0	'
Pharmaceutical [Member] | Operating Segments [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Product revenues	16,563		11,495	50,708		30,051	'
Revenue from services	0		0	0		0	'
Revenue from transfer of intellectual property	913		0	14,720		0	'
Operating (loss) income	-11,126		-1,755	-7,171		-5,072	'
Depreciation and amortization	2,020		1,780	5,417		4,805	'
Assets	1,087,950		'	1,087,950		'	142,299
Goodwill	174,734		'	174,734		'	32,844
Diagnostics [Member] | Operating Segments [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Product revenues	'		'	'		'	'
Revenue from services	2,710		43	8,870		173	'
Revenue from transfer of intellectual property	395		200	1,360		400	'
Operating (loss) income	-399		-3,810	-16,783		-12,835	'
Depreciation and amortization	1,717		841	5,110		2,510	'
Assets	114,434		'	114,434		'	112,422
Goodwill	$47,606		'	$47,606		'	$47,606
[1]	As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Segments_Details_Textual

Segments (Details Textual) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jun. 30, 2013

Dec. 31, 2012

Segment

Intersegment Elimination [Member]

Pharmaceutical [Member]

Diagnostics [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Segment

Segment

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Customer

Customer

Customer

Customer

Customer

Customer

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of reportable segments

'

'

2

'

'

'

'

'

'

'

'

'

'

Number of operating segments

'

'

'

'

'

2

2

'

'

'

'

'

'

Inter-segment sales

'

'

'

'

$0

'

'

'

'

'

'

'

'

Inter-segment allocation of interest expense

'

'

'

'

0

'

'

'

'

'

'

'

'

Inter-segment allocation of income taxes

$1,290,000

($128,000)

$2,258,000

$89,000

$0

'

'

'

'

'

'

'

'

Number of customer represented

'

'

'

'

'

'

'

0

0

0

0

0

0

Percentage of product revenue contributed by customer

'

'

'

'

'

'

'

10.00%

10.00%

10.00%

10.00%

10.00%

10.00%

Series_D_Preferred_Stock_Redem1

Series D Preferred Stock Redemption (Details) (USD $)	9 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Mar. 08, 2013	Mar. 08, 2013
				Common Stock [Member]	Series D Preferred Stock [Member]
Temporary Equity [Line Items]	'	'	'	'	'
Total cash dividend paid	$3,015	$0	'	'	$3,000
Convertible preferred stock	'	'	'	'	1,129,032
Shares of common stock	'	'	'	11,290,320	'
Preferred Stock, shares outstanding (in shares)	0	'	1,129,032	'	0